Annual Report 2021

ATOMO DIAGNOSTICS LIMITED

ACN 142 925 684

atomo



ATOMODIAGNOSTICS.COM

Equity ASA – Audio File

Co-Founder, Managing Director & CEO of Atomo Diagnostics John Kelly, talks about his unique background in diagnostic devices, their application to global health challenges such as HIV and COVID-19 and future opportunities in their exciting journey.

Channel Nine News 14 July 2021

Atomo CEO, John Kelly, calls for rapid test diagnosis door-to-door in South-West Sydney's hotspot.

ABC: The Business 30 August 2021

A report on the advantages of rapid antigen testing versus the expense and lag time of the commercial pathology model. The Federal Government faces calls from many sectors to subsidise rapid antigen tests with COVID-19 tests costing $993 million since March 2020. John Kelly makes the case for rapid tests to receive Government support as part of the overall management of the pandemic.

Channel Nine

Rapid testing trials underway in some aged care facilities in NSW and Victoria, July 2021.

CONTENTS

01	CHAIRMAN'S LETTER	3
02	CEO REPORT	5
03	COMPANY STRATEGY	8
04	KEY HIGHLIGHTS	9
05	A NEW RAPID TEST LANDSCAPE	12
06	DIRECTORS' REPORT	14
07	FINANCIAL STATEMENTS	34
	Statement of profit or loss and other comprehensive income	37
	Statement of financial position	38
	Statement of changes in equity	39
	Statement of cash flows	40
08	NOTES TO FINANCIAL STATEMENTS	41
09	DIRECTORS' DECLARATION	75
10	INDEPENDENT AUDITOR'S REPORT	77
11	SHAREHOLDER INFORMATION	83
12	CORPORATE DIRECTORY	86



VISION

Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing.

MISSION STATEMENT

Re-imagining diagnostics by putting the user point of care experience at the centre of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses and a seamless pathway to treatment.

VALUES

IMPACT
Commercialising products that matter to our users.

INNOVATION
Fostering creative thinking and solutions.

INTEGRITY
Ensuring honesty and fairness in all that we do.

COLLABORATION
Working as one global team.

EXCELLENCE
Being recognised as experts in the field.

COMMERCIALISING PRODUCTS THAT MATTER

"Sadly, stigma and embarrassment still prevents many people testing for HIV. The arrival of this self testing device is a critical step in removing a barrier to people knowing their status."

Australian Federation of AIDS Organisations

"Super easy quick test, top instructions and quickly implemented."

HIV Self-Test User, Germany, Amazon

01 CHAIRMAN'S LETTER

Dear Shareholders,

While I write to you, our shareholders, on behalf of my fellow Directors of Atomo Diagnostics Limited, I do so mindful of the challenging personal circumstances being experienced by many people as a result of the current pandemic. I sincerely wish you and your loved ones good health and wellness.

At Atomo, we have responded promptly to the opportunities and risks presented by the pandemic in Australia and elsewhere. We have worked with our partners around the world to ensure timely delivery of rapid tests where they are needed, serving across health regimes as a prompt, front-line strategy. We have welcomed the opportunity to demonstrate our ability to respond to community needs and the practical validation of rapid testing as an effective means to efficiently measure and help safeguard community health.

OUR BUSINESS

Atomo supplies devices for the rapid testing of medical conditions by professional users and consumers, detecting infectious diseases, chronic health conditions or assessing consumer wellness. Atomo has two business models for the development and commercialisation of diagnostic devices.

The first involves the sale of finished products, such as our HIV Self-Test, the second is the sale of original equipment manufacturer (OEM) devices. The corresponding marketing strategies allow Atomo to secure commercial opportunities that effect scale across our rapid test applications and geographies.

The accelerated take up during the pandemic of decentralised rapid testing allows Atomo and our customers valuable insights into how healthcare is changing. Participating within this change draws on our ever-evolving user-centric designs, extending the tests available on our platforms and development of new means to capture results and so further shorten time to treatment.

Atomo's approach to the development of devices and end delivery to users often sees us in partnership. The changing demands of the last year saw us working ever more closely with our partners. We announced that Atomo had supported Viatris Inc (a combination of Atomo's longstanding global health partner, Mylan Pharmaceuticals, and Pfizer's Upjohn Business) in securing a multi-year agreement with global health agency, Unitaid, to expand access to HIV self-testing in low- and middle-income countries. Atomo contracted with Access Bio Inc. to supply Atomo platforms to house COVID-19 antibody tests and also partnered with them for delivery of COVID-19 antigen tests to the Australian market.

> **In support of our growth, during the year we continued the expansion of our production capacity, giving us the ability to manufacture 1.3 million devices monthly.**

We continued to collaborate with one of our OEM partners, Lumos Diagnostics Holdings Ltd, while highlighting and congratulating them on their successful ASX listing.

OUR CAPABILITIES AND REGULATORY APPROVALS

Securing regulatory approvals from the TGA, by way of inclusion in the ARTG of Atomo COVID-19 Antibody and Antigen tests, allowed swift delivery of tests across Australia to meet diagnostic needs arising from the pandemic. Similarly, the Emergency Use Approval received from the US FDA for Access Bio's COVID-19 Antibody test on an Atomo platform.

In support of our growth, during the year we continued the expansion of our production capacity, giving us the ability to manufacture 1.3 million Atomo devices monthly.

Atomo's core capabilities are in developing and commercialising rapid diagnostics tests, the design of which prioritise ease of use and speed to deliver highly accurate results. The continued development of our established platform includes deployment of digital eHealth solutions. We are excited about extending the use of our devices beyond our established lateral flow blood test capability. Looking ahead, we will continue to draw from what we have learned during the pandemic about how to help lead the response to the growing need for point of care and user diagnostic testing.

OUR PEOPLE

We have expected ever more of the people who make up Atomo, its executives, management, and Board. They have responded promptly, making sense of rapidly changing circumstances, of communicating and collaborating to continue to develop and deliver vitally needed diagnostic tests.

These efforts are under the indefatigable leadership of John Kelly, Will Souter and Mark Smith. I thank my fellow Directors Curt LaBelle, Paul Kasian and Connie Carnabuci and our Company Secretary, Gillian Nairn, whose experience and wisdom shared generously and continuously shapes Atomo as it is today.

As we have again seen throughout the last year and now, Atomo continues to be successfully navigated through changing conditions, while identifying, assessing, and acting on new opportunities. We welcome your ever continuing support and hope that you share our excitement.

John Keith

John Keith
Chair, Atomo Board

> At Atomo, we have responded promptly to the opportunities and risks presented by the pandemic in Australia and elsewhere.

02 CEO REPORT

The 2021 financial year represented Atomo's first full year as a publicly listed company on the Australian Securities Exchange (ASX). During the period, Atomo continued to invest in the scale-up of its operational capabilities to underpin ongoing growth, achieving a number of key milestones. This includes the qualification of its HIV Self-Test production facility in South Africa; completing operational enhancements to its integrated blister reagent manufacturing process and commencing manufacture of a new blister machine here in Sydney; as well as quadrupling the installed production capacity for Atomo devices. The total available monthly capacity for our Galileo and Pascal devices is now 1.3 million units.

In conjunction with our commercial partners Atomo also delivered several significant contract wins during the year that will provide a foundation for growth over the coming years. This includes Atomo and Viatris being selected by Unitaid (a global health agency focused on improving health outcomes in low and middle income countries – LMIC's) as one of only two critical suppliers of HIV Self-Tests to support its programme to expand access to HIV self-testing in LMIC's. Initial orders from Viatris commenced in Q4 FY21 with the first supply from Atomo very late in Q4 FY21 and expanding into Q1 FY22.

In July 2020, Atomo entered into a partnership agreement with Access Bio to supply its CareStart™ EZ COVID-19 IgM/IgG antibody test to the US market on the Atomo Galileo platform. An initial batch was delivered to Access Bio in Q3 FY21, ahead of the Emergency Use Approval (EUA) from the FDA, which was received very late in Q4 FY21. Notably, this also heralded the first ever U.S. Food and Drug Administration (FDA) approval of a rapid test utilising an Atomo device.

We expect this regulatory validation of Atomo's products to be further reinforced in the coming months with the anticipated FDA approval of our Pascal platform via the Lumos FebriDx Viral vs. Bacterial rapid test which is currently being reviewed for approval by the US FDA.

In addition to sales of Atomo devices during the year to partners in France and the US for rapid COVID-19 Antibody testing, Atomo has also successfully registered products here in Australia via the Therapeutics Goods Administration (TGA) on the Australian Register of Therapeutic Goods (ARTG) for supply for professional use in Australia. This includes the Atomo COVID-19 Antibody rapid test and the Atomo COVID-19 Antigen rapid test. Approximately 50,000 tests were sold throughout the FY21 year, with the company seeing a very significant increase in sales in early FY22 due to the Delta variant outbreak. The company continues to engage with TGA towards achieving a pathway to self-test use approval for an Atomo COVID-19 Antigen rapid test potentially during FY22.

> **The COVID-19 pandemic has fundamentally changed how healthcare is being delivered and has materially changed the diagnostics landscape and increased the size of the diagnostics market.**

We are also pleased to report on the continued improvement in our financial performance, detailed in this report. In FY21, revenue from sales to customers increased by 25% to $6.7m, with cash receipts from sales to customers for the year totalling $8.1m. Revenue growth was driven by:

- expanding sales of COVID-19 products in Australia, and devices to partners in Europe and the US ($3.7m);
- ongoing HIV Self-Test sales, particularly in global health markets via Viatris ($1.1M); and
- sales to key OEM partners including Lumos Diagnostics ($2.0m).

Gross margins remained above 50% reflecting a broadening of revenues across a greater number of products and devices.

During FY21, the business continued to make progress on other key objectives, including:

- ongoing critical R&D activities, including the continued development of best-in-class devices for additional non-blood samples types as well as investment in our next generation proprietary blister machine to support scale up in the production of blisters for use in our Pascal, Elion and possible future devices requiring integrated reagent delivery functionality;
- technical and commercial engagement progressed with several leading US headquartered diagnostics companies seeking access to Atomo's rapid blood test platforms and its proprietary functionality for non-blood test applications, reflecting increased industry interest in user and home focused diagnostic solutions;
- continued focus and efforts related to US market engagement including the development of a US market entry strategy, securing US go-to-market channels and set up of critical business development/ commercial resourcing and local entity infrastructure necessary to support US market entry; and

"The Company is developing its first non-blood rapid test platforms, commercialising integrated easy to use swab and saliva rapid solutions to expand the addressable market.

- development of its first non-blood rapid test platforms to expand its portfolio across growing point-of-care test (POCT) markets. Commercialising platforms for swab and saliva based rapid tests will enable the Company to expand the addressable market covered by its unique integrated user-friendly solutions and better partner with larger companies operating with multiple sample types in the market.

A GROWING TREND IN TELEHEALTH

The COVID-19 pandemic has fundamentally changed how healthcare is being delivered, including the diagnostics landscape, especially in the US. The various phases of the pandemic have radically accelerated global awareness of the critical importance of rapid, accurate and reliable diagnostic tests, and there is a much greater focus on and consumer acceptance of at-home testing and reducing reliance on facilities-based health care visits.

Public health acknowledgment of the need for and value of home-based solutions, initially in the US and Europe and now more recently seen in Australia, has resulted in significant growth in the size and importance of the home-based diagnostic market.
This has resulted in a reassessment of the attractiveness and value of proven user focused diagnostic solutions and has reinforced to the market the critical need for proven user friendly point of care and home-based diagnostics as part of a broader healthcare offering.

With a range of new over the counter and home tests approved for COVID-19 testing in the US and expanded government reimbursement for home telehealth consultations driving market growth, there is a notable increase in consumer acceptance and demand for home testing. This opens a significant new vertical to market with growing consumer demand for a wider range of simple to use rapid tests. Atomo is well positioned to address this growing market segment with proven, world-leading technology.

LOOKING INTO FY22

We enter FY22 experiencing increased commercial momentum across the business, including tailwinds coming from the rapid expansion in COVID-19 related business particularly in the Australian market; the recently awarded Unitaid tender driving HIV Self-Test demand; and the ramp up in interest in our various OEM offerings from current and potential new partners, particularly in the US.

We are excited to progress our journey as we move through FY22. During the coming year we are planning to:

- continue the expansion of strategic commercialisation partnerships across key global markets, with emphasis on our seeking to secure US market entry partnerships for our products and technology;
- leverage substantial installed production capacity to drive accelerated OEM partnerships/ supply contracts, and to further commercialise Atomo devices and key proprietary components across key growing POCT segments, including infectious diseases and telehealth supported home testing;
- continue to help lead Australia's rapid testing response to the increasingly impactful COVID-19 pandemic in Australia, through the expansion of testing solutions across key channels including a focus on supporting at-home antigen testing given Atomo's proven capabilities in the consumer self-test market;
- expand the addressable market Atomo operates in through the development and of new Atomo platforms for non-blood rapid test applications – focus on integrated user-friendly solutions for swab and saliva rapid test applications supporting COVID-19 and other common respiratory conditions, as well as commercialisation of our digital health APP to support at home diagnostic use; and
- establish Atomo's US business and infrastructure and support US commercial, sales, and technical development capabilities.

On behalf of the Atomo Board and management I would like to express our sincere gratitude to our dedicated staff, partners, suppliers, customers, and shareholders for your support throughout the year, and look forward to reporting on another successful year in FY22.

John Kelly
CEO, Atomo

03 COMPANY STRATEGY

Atomo's focus is to grow through innovation and creativity, bringing best-in-class rapid testing technology to those who need it most. By putting the user first, Atomo has reimagined blood-based diagnostics to deliver simple, effective and accurate diagnostic devices. Atomo is leveraging that same thinking beyond blood, by turning to innovate in the fields of saliva and swab sampling.

The Company's strategy is to bring its technology to market by focusing on three core areas:

- infectious disease testing, initially HIV and COVID-19;
- supplying devices and componentry to key OEM partners; and
- entering new growth markets where usability is critical, including consumer health and wellness testing.

Growing our partnerships is the key to truly building scale in these core areas and in new markets. Atomo values our existing channel partners in infectious diseases and OEM supply. Further, we seek to replicate these partnerships as we expand into consumer health and wellness markets that are emerging through the growth of telehealth, home health and digital channels.

STRATEGIC FOCUS

CAPABILITIES

Innovation & Commercialisation
(Device design, regulatory, usability, ehealth, IP)

REGULATORY PATHWAY

MARKETS

Infectious Disease Tests
(HIV, COVID, Others)

OEM Supply
(Devices, components)

Consumer Health & Wellness Tests
(Entering new market)

CHANNELS

- Channel partners
- Direct to consumers
- Co-commercialisation partners

- Atomo in-house supply
- OEM device partners
- Custom developments/ licensing

- Telehealth/home health
- Online wellness
- Pharmacy/retail

04 KEY HIGHLIGHTS

ATOMO COVID-19 RAPID TESTS
Rapid tests were added by the TGA to the ARTG in the first half of FY21 for supply in Australia. The antibody product was launched in Q2 FY21. Sales of primarily antibody test units approximate 50,000 in the second half FY21. Antigen test demand commenced towards year end, stepping up very significantly in Q1 FY22, due to the Delta outbreak.

ACCESS BIO INC. (USA) AGREEMENT AND SUPPLY
A partnership was signed in Q1 FY21 for COVID-19 antibody RDT tests on the Atomo platform in the North American market. The initial product was delivered in Q3 FY21, in advance of US FDA EUA, which was granted very late in Q4 FY21.

UNITAID (HIV)
A Global Health Agreement was signed between Mylan (Viatris)/Atomo and Unitaid in Q4 FY21, for access to Atomo's HIV Self Tests in more than 135 countries. Initial orders commenced with the first supply in late Q4 FY21, expanding into Q1 FY22.

ATOMO'S CAPE TOWN HIV FACILITY EXPANSION
Expansion was validated and capacity was ramped up.

OEM BUSINESS
Technical and commercial engagement is progressing, with several leading multinational diagnostics companies seeking access to Atomo's rapid blood test platforms and proprietary functionality for non-blood test applications.

USA MARKET ENTRY
To support expanded engagement in the United States market, business development/ commercial resourcing and local entity infrastructure is being established.

NEW PRODUCT DEVELOPMENT
Atomo commenced development of its first non-blood rapid test platform in Q4 FY21.

FINANCIALS
Sales growth of 25%, cash receipts of ~$8m and cash at bank of $18m.

Atomo's wholly owned HIV Self-Test facility, Cape Town, South Africa

HIV TESTING

HIV business performance (FY21)

Sales revenue – $1.08m

Units sold – 268k

HIV Self-Test

Lower and Middle Income Country demand for HIV self-tests is anticipated to more than double over the next 5 years.

Atomo is one of only two test providers in the Unitaid global procurement program.

The only HIV self-test approved in Australia (TGA), Atomo's HIV self-test is also approved in Europe (CE Mark) and prequalified by the World Health Organisation (WHO).

Atomo's agreement with Viatris (Mylan) spans more than 135 countries.

In developed markets, Atomo is assessing opportunities to partner in the rapidly growing PrEP and on-line channels and is seeking commercial partnerships to support market entry of its HIV products in the US and China.

OEM

OEM business performance (FY21)

Sales revenue – $1.98m

Units sold – 1.1m

Having successfully entered into OEM supply agreements with a number of early adopters, Atomo is now engaging with a number of larger listed diagnostic partners, who have interest in accessing Atomo's platforms and IP-backed rapid test functionality. Production capacity has increased during the year and is now at 1.3m devices per month, positioning Atomo to support growing customer demand.

Significantly, the first US FDA approval for a rapid test on an Atomo platform was obtained during the year, with Access Bio's antibody test on the Atomo Galileo device receiving Emergency Use Authorisation at the very end of FY21, further endorsing regulatory acceptance of Atomo's core technology. Our partner Lumos Diagnostics is seeking FDA approval for their FebriDx test on Atomo's Pascal platform. If successful, FDA approvals will then have been granted for tests on both the Atomo Galileo and Atomo Pascal platforms, which positions Atomo extremely well for engagement with other potential OEM partners in the US market. To support the pursuit of these growth opportunities in the large and growing US market, Atomo is looking to establish a dedicated US team during FY22.

COVID

COVID-19 business performance (FY21)

Sales revenue – $3.68m

OEM units sold – 1.1m

Test products units sold – 50k

Revenue from COVID-19 related sales was generated from a number of international markets as well as locals sales commencing in H2 FY21. 1.1m units were sold to NG Biotech and Access Bio for European and North American markets as early demand emerged for antibody testing. Later in 2020, Atomo's COVID-19 antibody and antigen rapid test were listed on the ARTG by the TGA. The majority of local sales were antibody tests during FY21, with only a limited number of antigen tests sold. Early in FY22, as the Delta outbreak emerged as the dominant variant and as a shift in public policy in favour of rapid testing occurred, local demand for rapid antigen testing ramped up significantly.

OUR PEOPLE – OUR GREATEST ASSET

Atomo staff span Australia, South Africa, the United Kingdom and the United States. As for many employees across the globe, FY21 was a challenging time.

We were fortunate to enjoy some face to face events such as our International Womens Day and our end of year celebrations recognising the commitment of our team.

We implemented activities to ensure we stayed connected while working from home: weekly 'colleague coffee catchups', 'fortnightly Friday fun' online games, and our Inaugural global step challenge.

We are grateful our people continue to rise to these challenges, demonstrating resilience, innovation and teamwork.

International Women's day in Cape Town and Sydney (below)

Atomo staff at the Cape Town facility, South Africa (below)

Recognising and embracing the diversity of our people – Wear it Purple Day (above)

05 A NEW RAPID TEST LANDSCAPE

MARKET TRENDS ACCELERATED BY THE PANDEMIC

- **Growing acceptance** from Governments internationally and in Australia that rapid testing has a role to play in the healthcare ecosystem
- Changes in **regulatory environment** to support the delivery of healthcare remotely and in the home, with telehealth appointments being approved for reimbursement in many jurisdictions.
- Increased **customer acceptance**, willingness and desire to take control of their own health at home
- Atomo is **uniquely positioned** to meet this market, with simplicity, usability and accuracy at the heart of everything we do.

Telehealth has emerged as a disruptive and permanent channel for health delivery, with a generation of consumers opting for mobile-friendly, home-based health care options – as illustrated below.

TELEHEALTH: ACCEPTED PART OF HEALTH ECOSYSTEM



Source: McKinsey & Co. Telehealth: A quarter-trillio-dollar post-COVID-19 reality? May 2021

> Telehealth visits appear to be stabilising at levels well above those pre-pandemic, and health equity and inequity is coming into focus.
>
> CB Insights, State of Telehealth Q2 20

> As a result of using Atomo Rapid testing, which the Government is soon introducing into high-risk settings, we've been able to support people, as well as ensuring all care and clinical agency staff are rapid tested before entry into our homes.

Southern Cross Care NSW & ACT

06 DIRECTORS' REPORT

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Atomo Diagnostics Limited (referred to hereafter as the 'Company' or 'Parent Entity') and the entities it controlled at the end of, or during, the year ended 30 June 2021.

All amounts are presented in Australian dollars (AUD) unless otherwise stated.

DIRECTORS

The following persons were Directors of the Company during the year and up to the date of this report. The Directors were in office for this entire period unless otherwise stated:

Director	Appointed	Resigned
John Keith (Chair & Non-Executive Director)	2 December 2011	n/a
John Kelly (Managing Director)	1 April 2010	n/a
Curt LaBelle (Non-Executive Director)	21 October 2016	n/a
Paul Kasian (Non-Executive Director)	4 February 2020	n/a
Connie Carnabuci (Non-Executive Director)	4 February 2020	n/a

The Company Secretary is Gillian Nairn, who was appointed on 4 February 2020.

OPERATING & FINANCIAL REVIEW

Principal activities

The principal activities of the Group during the course of the year were the development and sale of medical devices.

There were no significant changes in the nature of the activities of the Group during the year.

Review of operations

The loss for the Group after providing for income tax amounted to $6,021,215 (2020: loss of $9,218,105).

Revenue from customers increased by 25.1% for the year, from $5.37 million in 2020 to $6.72 million in 2021. This growth in revenue was driven by:

- demand for the Group's devices from customers in Europe and North America for the production of COVID-19 antibody tests;
- sales in Australia of Atomo branded COVID-19 rapid antibody and antigen tests;
- growth in demand from other OEM customers for the Group's devices for use in their finished products; and
- sales of the Group's HIV products in Australia and internationally through global health channels and in the European market.

Cash and cash equivalents as at 30 June 2021 amounted to $17.9 million compared to $27.1 million as at 30 June 2020. The decrease in cash and cash equivalents during the year is attributable to substantial investment in intangibles and plant and equipment as the business continued its research and development activities, accelerated scale-up in manufacturing capacity and as a result of ongoing operating losses as the business drives forward with a growth agenda.

Significant changes in the state of affairs

- On 4 September 2020, the Company issued 320,000 ordinary shares to various employees under the Company's Exempt Employee Share Plan. None of these shares were issued to key management personnel.
- During the period, 7,200,000 options were exercised resulting in the issue of 7,200,000 ordinary shares and a $1.31 million cash contribution when the exercise price was paid.
- On 31 May 2021, the Company issued 4,000,000 options to Bondi Partners in consideration for provision of strategic advisory services. These options were issued as part of Bondi

Partners' appointment to assist with the development and execution of Atomo's US go-to-market strategy and commercial engagements across both public and private sectors. Tranche 1 (2,000,000 options) will vest on 31 October 2022 subject to Atomo extending Bondi Partners' consultancy engagement for a further period of at least six (6) months (in Atomo's sole discretion). These options are excercisable at an exercise price of $0.40 per option and expire on 30 April 2024. Tranche 2 (2,000,000 options) are excercisable at $0.60, vest on 30 April 2022 and expire on 30 April 2024.

In the opinion of the Directors, there were no other significant changes in the state of affairs of the Group during the financial year.

Matters subsequent to the end of the financial year

- Mr Fabio Baglioni, a former executive of the Group, resigned on 30 July 2021. Consequently, 1,600,000 options issued to Mr Baglioni under the Company's Post-IPO option plan, lapsed.
- 1,733,333 options issued to executives under the Company's Post-IPO option plan lapsed as the KPIs applicable to the options were not satsified with respect to the year ended 30 June 2021.
- The Board has exercised its discretion to allocate 759,999 options to executives under the Company's post-IPO option plan to reward the diligent execution of the corporate strategy and to ensure retention of the key talent needed to deliver strategic outcomes in the interest of shareholders.

No other matter or circumstance has arisen since 30 June 2021 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Impacts of COVID-19

Atomo's activities continued throughout FY21 nothwithstanding the COVID-19 pandemic. There were some delays in activity caused by the pandemic, for example, the global tender for HIV Self Tests run by Unitaid was substantially delayed, the consequence of which was that Atomo's revenue from that tender was modest and primarily occured at the very end of the financial year. That said, a significant portion of additional revenue was driven by demand for Atomo's COVID-19 products in Australia and for its platforms for use by OEM customers in their own COVID-19 rapid tests internationally.

Likely developments and expected results of operations

As Atomo moves into the new financial year, it remains in a very strong financial position and, having invested substantially during the period in scaling up capacity, is well placed to leverage that capacity in FY22. The primary focus moving into FY22 will be on:

- ramping up production and supply into the global HIV self-test market following Viatris' success late in FY21 in the Unitaid tender, for which Atomo is the sole manufacturer and supplier of the HIV self-tests;
- increase access to new markets globally for its devices, in particular in North America where investment is underway in business development and market entry opportunities, particularly in light of the rapid expansion in acceptance and uptake of at-home testing, telehealth and self-testing;
- ongoing investment and resourcing applied to research and development aimed at continuing to develop best-in-class user friendly diagnostic devices for a variety of sample types, expanding beyond blood into saliva and swab samples; and
- continue to supply into demand created by COVID-19 internationally and domestically in light of ongoing global testing requirements driven by the increased prevalence of the Delta strain of the virus.

ENVIRONMENTAL REGULATION

The Group's operations are not subject to any significant environmental regulation under Australian Commonwealth or State law. The Board believes that the Group has adequate systems in place for the management of its environmental requirements.

INFORMATION ON DIRECTORS

Name: John Keith

Title: Non-Executive Chair

Experience and expertise: John Keith has served as a Non-Executive Director of Atomo since December 2011 and became Chair in 2014.

Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the Boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation.

Mr Keith holds a Bachelor of Arts (Hons) majoring in Economic History from the Victoria University of Wellington, a Master of Applied Finance from Macquarie University and a Global Executive MBA from the University of Sydney.

Other current directorships: Nil

Former directorships (last 3 years): Nil

Special responsibilities: Member of the Audit and Risk Committee and Member of the People, Culture & Remuneration Committee.

Interests in shares: 3,261,056

Interests in options: 3,600,000

Contractual rights to shares: Nil

Name: John Kelly

Title: Managing Director and CEO

Experience and expertise: John Kelly is the Managing Director and CEO of Atomo.

For more than 20 years Mr Kelly has focused on developing and commercialising medical devices to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products.

Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill',

the world's first glass prefilled drug delivery device with integrated auto retract safety feature, and this technology was successfully licensed to Sanofi Aventis for US$47 million. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the ground-breaking Mirage Swift and Activa mask systems.

Mr Kelly holds an Honours degree in Mechanical Engineering from the University of Liverpool, a Master's degree in Manufacturing Systems Engineering from Queen's University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School's inaugural 'Excellence in Leadership' scholarship.

Other current directorships: Nil

Former directorships (last 3 years): Nil

Special responsibilities: Nil

Interests in shares: 73,530,248

Interests in options: 1,333,333

Contractual rights to shares: Nil

Name: Curt LaBelle

Title: Non-Executive Director

Experience and expertise: Curt LaBelle has served as a Non-Executive Director of Atomo since October 2016.

Dr LaBelle has been actively involved in the healthcare industry for over 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF), a social impact investment fund, which manages approximately US$108 million backed by the Gates Foundation, JP Morgan and others. He also serves as a Director on the Boards of Z Optics, Evenovia, Revelation Bio and Atticus Medical.

Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former Director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen).

As Dr LaBelle is President at GHIF, a substantial shareholder of Atomo, Dr LaBelle is not considered to be an independent Director.

Dr LaBelle holds a Bachelor of Economics from Brigham Young University, and Doctor of Medicine and Master of Business Administration degrees from Columbia University.

Other current directorships: Director of Eyenovia Inc. (NASDAQ:EYEN)

Former directorships (last 3 years): Former chairman of Exagen Inc. (NASDAQ: XGN) Special responsibilities: Member of the Audit and Risk Committee

Interests in shares: 65,051,280

Interests in options: 2,400,000

Contractual rights to shares: Nil

Name: Paul Kasian

Title: Non-Executive Director

Experience and expertise: Dr Kasian is an experienced Executive Director with demonstrated success in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles.

His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management.

He holds a PhD in Microbiology and a Master of Business Administration, both from the University of Melbourne, and is a Graduate Member of the Australian Institute of Company Directors.

Other current directorships: Dr Kasian is currently Non-Executive Director (appointed 31 August 2016) and Chair (appointed 15 September 2018) of IODM Limited (ASX: IOD). He is also Non-Executive Director of Zucero Therapeutics Ltd (appointed 10 March 2021) and Eco Systems Ltd (appointed 16 October 2019).

Former directorships (last 3 years): Previously he served as a Non-Executive Director, then Chairman and CEO of GeneticTechnologies Limited (appointed 12 December 2013 and resigned 23 September 2019).

Special responsibilities: Chair of the Audit and Risk Committee

Interests in shares: 100,000

Interests in options: Nil

Contractual rights to shares: Nil

Name: Connie Carnabuci

Title: Non-Executive Director

Experience and expertise: Connie Carnabuci has over 35 years' experience advising intellectual property and technology intensive businesses in Australia and across Asia on commercial, corporate and regulatory matters.

She was recognised by the 2021 Australasian Law Awards as one of the most influential lawyers in Australia.

She is a professional Non-Executive Director and currently serves on the Board and Remuneration Committee of OFX Group Limited (ASX: OFX). Ms Carnabuci is the former General Counsel of the Australian Broadcasting Corporation and a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer.

She is a member of the Business Advisory Council of the UNSW Business School.

She was a Director and the Chair of the NFP, Kids Giving Back, from 2015 to 2018.

Ms Carnabuci is a graduate of UNSW (B.Commerce (Marketing), with merit/ LLB, 1986) and the Australian Institute of Company Directors.

Other current directorships: Ms Carnabuci currently serves as a Non-Executive Director on the Board, and the Remuneration Committee of OFX Group Limited (ASX: OFX).

Former directorships (last 3 years): Nil

Special responsibilities: Chair of the People, Culture & Remuneration Committee.

Interests in shares: 75,000

Interests in options: Nil

Contractual rights to shares: Nil

Other current and former (last 3 years) directorships quoted above are directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Company Secretary

Gillian Nairn has over 20 years' legal and governance experience in various listed and public companies, as well as in private practice.

Ms Nairn is a founder and Director of Dolmatoff Nairn Corporate Governance, a company secretarial service provider. Prior to founding Dolmatoff Nairn Corporate Governance, Ms Nairn held various company secretarial roles, predominantly with listed entities, in a variety of sectors including healthcare, manufacturing, resources, professional services and education.

Ms Nairn holds a Bachelor of Laws and Bachelor of Arts from UNSW and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia and holds a current NSW legal practising certificate.

Ms Nairn was appointed as Company Secretary on 4 February 2020.

MEETINGS OF DIRECTORS

The number of meetings of the Company's Board of Directors ('**the Board**') and of each Board Committee held during the year ended 30 June 2021, and the number of meetings attended by each Director were as per the table on the following page.

	Board		Audit & Risk Committee		People, Culture & Remuneration Committee	
	Held^	Attended	Held^	Attended	Held^	Attended
John Keith	13	13	7	7	3	3
John Kelly	13	13	-	-	-	-
Curt LaBelle	13	13	7	7	-	-
Connie Carnabuci	13	13	-	-	3	3
Paul Kasian	13	13	7	7	3	3

^ Represents the number of meetings when the director was eligible to attend as a member of the relevant committee.

REMUNERATION REPORT (AUDITED)

This Remuneration Report details the remuneration arrangements of the key management personnel of the Group, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key management personnel ('**KMP**') are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including all Directors of the Company.

The KMP of the Group during the financial year consisted of the following Directors of the Company:

- John Keith – Non-Executive Chair
- John Kelly – Co-Founder and Managing Director
- Curt LaBelle – Non-Executive Director
- Paul Kasian – Non-Executive Director
- Connie Carnabuci – Non-Executive Director

And the following executives:

- William Souter – Chief Financial Officer
- Mark Smith – Chief Operating Officer
- Fabio Baglioni – Chief Commercial Officer (Resigned on 30 July 2021)

The information in this Remuneration Report is set out under the following headings:

- Remuneration governance
- Non-Executive Directors' remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional disclosures relating to KMP

Remuneration Governance

To assist the Board in fulfilling its responsibilities in respect of remuneration and nomination related matters, shortly prior to listing, the Board established a Nomination and Remuneration Committee. During the financial year, on the recommendation of the Nomination and Remuneration Committee, the Board extended the scope of the Nomination and Remuneration Committee's responsibilities to include monitoring and making recommendations to the Board in relation to:

(i) recruitment, retention and termination policies and practices for Executive Directors and direct reports to the Managing Director and the alignment of the policies and practices with the promotion and sustainment of a culture aligned with Atomo's values, the promotion of long-term sustainable success and the achievement of the Company's business objectives;

(ii) people strategies and practices, which will instil and reinforce the Company's purpose and values, ensure health and wellbeing (physical and mental) and support the achievement of the Company's long-term business objectives; and

(iii) the development of, and progress in meeting, the Company's diversity objectives.

To reflect the extended scope of the Nomination and Remuneration Committee's responsibilities, the Board renamed the Committee the 'People, Culture & Remuneration Committee' and the Board resumed nomination responsibilities.

The members of the People, Culture and Remuneration Commitee at the date of this report are:

- Connie Carnabuci (Chair)
- John Keith
- Paul Kasian

The role and responsibilities, composition, structure and membership requirements of the People, Culture and Remuneration Committee are documented in the People, Culture and Remuneration Committee Charter available on Atomo's website at: https://atomodiagnostics.com/governance/

The People, Culture and Remuneration Committee Charter provides that the Committee should comprise at least three members, all of whom are Non-Executive Directors and a majority of whom are independent Directors, and the Chair of the Committee should be an independent Director who is not Chair of the Board.

All of the current members of the PCRC have been assessed by the Board as being independent Non-Executive Directors and the Chair of the Committee is not Chair of the Board.

Principles used to determine the nature and amounts of remuneration

Non-Executive Directors' remuneration

Each of the Non-Executive Directors has entered into appointment letters with Atomo confirming the terms of their appointment and their roles and responsibilities. The appointment letters are on standard commercial terms.

The Chair, John Keith, receives an annual fee of $130,000 and each Non-Executive Director receives an annual fee of $50,000.

Each Chair of a Board Committee receives an additional amount of $20,000 per annum. The Chairs of the Board Committees are Paul Kasian (Audit and Risk Committee) and Connie Carnabuci (People, Culture and Remuneration Committee).

Directors may also be reimbursed for expenses properly incurred by them in dealing with the Company's business or in carrying out their duties as a Director.

Under the Constitution, the Board decides the amount paid to each Non-Executive Director as remuneration for their services as a Director. However, under the ASX Listing Rules, the total amount of fees paid to all Non-Executive Directors for their services must not exceed in aggregate in any financial year the amount fixed by the Company's shareholders in general meeting. This amount has been fixed initially in the Company's Constitution at $500,000 per annum in aggregate and may be varied by ordinary resolution in a general meeting.

Executive remuneration

The Group aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits;
- short-term performance incentives;
- long-term performance incentives; and
- other remuneration such as superannuation and long service leave.

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, is reviewed annually by the People, Culture and Remuneration Committee based on individual and business unit performance, the overall performance of the Group and comparable market remunerations.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the the Group and provides additional value to the Executive.

The Company's short-term incentives ('**STI**') plan is designed to align the targets of the business units with the performance hurdles of executives. STI payments are granted to executives based on specific targets and key performance indicators ('**KPI's**') being achieved. Details of STIs paid to executives during the year can be found under the heading 'Amounts of remuneration' below.

The Company's long-term incentive ('**LTI**') plan includes share-based payments. Upon Atomo's admission to ASX, Atomo increased the fixed remuneration of its executives to align their remuneration with the market, and granted each of the executives an allocation of options under Atomo's Employee Share Option Plan ('**ESOP**'). Further details can be found under the heading 'Share-based compensation' below.

Details of remuneration

Amounts of remuneration

Details of the remuneration of the KMP of the Group are set out in the following tables. Where individuals were KMP for only part of the year, only remuneration relating to that period is included in the tables below.

	Short Term Benefits			Post-employment benefits	Long-term benefits	Share-based payments		
2021	Cash salary and fees $	Cash bonus $	Non-monetary $	Super-annuation $	Long service leave $	Equity-settled shares $	Equity-settled options $	Total $
Non-Executive								
John Keith	130,000	-	-	-	-	-	20,337	150,337
Curt LaBelle*	50,000	-	-	-	-	-	22,730	72,730
Paul Kasian	63,927	-	-	6,073	-	-	-	70,000
Connie Carnabuci	70,000	-	-	-	-	-	-	70,000
Executive Directors								
John Kelly	372,262	84,000	-	36,438	7,023	-	(32,422)	467,301
Other Key Management Personnel								
William Souter	280,902	45,000	-	26,027	601	-	(25,938)	326,592
Mark Smith	287,360	41,391	-	-	257	-	(25,938)	303,070
Fabio Baglioni	230,480	-	-	-	-	-	(25,938)	204,542
	1,484,931	**170,391**	**-**	**68,538**	**7,881**	**-**	**(67,169)**	**1,664,572**

*Amounts included under 'Equity-settled options' include amounts paid to GHIF, of which Curt LaBelle is President.

2020	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments		
	Cash salary and fees $	Cash bonus $	Non-monetary $	Super-annuation $	Long service leave $	Equity-settled shares $	Equity-settled options $	Total $
Non-Executive								
John Keith	32,500	-	-	-	-	-	21,772	54,272
Curt LaBelle*	12,500	-	-	-	-	-	19,450	31,950
Paul Kasian	15,982	-	-	1,518	-	-	-	17,500
Connie Carnabuci	17,500	-	-	-	-	-	-	17,500
George Sidis**	-	-	-	-	-	-	3,023	3,023
Doris-Ann Williams		--	-	-	-	-	9,821	9,821
Executive Directors								
John Kelly	298,083	209,384	-	46,101	24,955	-	32,422	610,945
Other Key Management Personnel								
William Souter	94,651	-	-	8,309	1,401	-	25,938	130,299
Mark Smith	208,924	-	-	-	-	-	25,938	234,862
Fabio Baglioni	91,565	-	-	-	-	-	25,938	117,503
	771,705	**209,384**	**-**	**55,928**	**26,356**	**-**	**164,302**	**1,227,675**

*Amounts included under 'Equity-settled options' include amounts paid to GHIF, of which Curt LaBelle is President.

**Amounts included under 'Equity-settled options' include amounts paid to ID&E Pty Ltd, which is controlled by George Sidis.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration 2021	Fixed remuneration 2020	At risk - STI 2021	At risk - STI 2020	At risk - LTI 2021	At risk - LTI 2020
Non-Executive Directors						
John Keith	100%	100%	-	-	-	-
Curt LaBelle	100%	100%	-	-	-	-
Paul Kasian	100%	100%	-	-	-	-
Connie Carnabuci	100%	100%	-	-	-	-
George Sidis	100%	100%	-	-	-	-
Doris-Ann Williams	n/a	100%	n/a	-	n/a	-
Executive Directors						
John Kelly	89%	59%	18%	35%	-7%	6%
Other Key Management Personnel						
William Souter	94%	79%	14%	-	-8%	21%
Mark Smith	95%	89%	14%	-	-9%	11%
Fabio Baglioni	100%	78%	-	-	-	22%

Cash bonuses are dependent on meeting defined performance measures. The maximum bonus values are established at the start of each financial year and amounts payable to KMPs are determined by the Board in consultation with the People, Culture and Remuneration Committee.

The proportion of the cash bonus paid/payable or forfeited is as follows:

Name	Cash bonus paid/payable 2021	Cash bonus paid/payable 2020	Cash bonus forfeited 2021	Cash bonus forfeited 2020
Non-Executive Directors				
John Keith	-	-	-	-
Curt LaBelle	-	-	-	-
Paul Kasian	-	-	-	-
Connie Carnabuci	-	-	-	-
George Sidis	-	-	-	-
Doris-Ann Williams	-	-	-	-
Executive Directors				
John Kelly	100%	100%	-	-
Other Key Management Personnel				
William Souter	75%	-	-	-
Mark Smith	75%	-	-	-
Fabio Baglioni	-	-	-	-

SERVICE AGREEMENTS

Remuneration and other terms of employment for KMPs are formalised in service agreements. Details of these agreements are as:

Name:	**John Kelly**
Title:	Managing Director
Employment commenced:	1 October 2011
Term of agreement:	Not specified.
Details:	Annual salary of $420,000 (including superannuation) plus a cash bonus of up to 20% of base salary (subject to the satisfaction of performance criteria), to be reviewed annually by the People, Culture & Remuneration Committee. John Kelly is entitled to participate in the Company's share and option plans. Please refer to the section titled 'Share-based compensation' for further details. Ten (10) week termination notice by either party however this notice period does not apply if the employment is terminated for serious and wilful misconduct or any conduct by John Kelly that amounts to fraud, theft, violence, harassment, gross negligence or any other action that may otherwise bring the Company into disrepute.

Name:	**William Souter**
Title:	Chief Financial Officer
Employment commenced:	10 March 2020
Term of agreement:	Not specified.
Details:	Annual salary of $300,000 (including superannuation) plus a cash bonus of up to 20% of base salary (subject to the satisfaction of performance criteria), to be reviewed annually by the People, Culture & Remuneration Committee. William Souter is entitled to participate in the Company's share and option plans. Please refer to the section titled 'Share-based compensation' for further details. Ten (10) week termination notice by either party however this notice period does not apply if the employment is terminated for serious and wilful misconduct or any conduct by William Souter that amounts to fraud, theft, violence, harassment, gross negligence or any other action that may otherwise bring the Company into disrepute.

Name:	**Mark Smith**
Title:	Chief Operating Officer
Employment commenced:	1 October 2019
Term of agreement:	Not specified.
Details:	Annual salary of GBP 150,000 plus a cash bonus of up to 20% of base salary (subject to the satisfaction of performance criteria), to be reviewed annually by the People, Culture & Remuneration Committee. Mark Smith is entitled to participate in the Company's share and option plans. Please refer to the section titled 'Share-based compensation' for further details. The agreement will terminate automatically without further action if the parties mutually agree to terminate the agreement. Additionally, either party may terminate the agreement: a. by providing eight (8) weeks' notice; or b. by providing written notice, if the other party has breached the agreement and either the breach is not capable of rectification or the other party had not complied with a notice to perform or rectify the breach.

Name:	**Fabio Baglioni**
Title:	Chief Commercial Officer
Employment commenced:	17 February 2020
Agreement terminated:	30 July 2021
Term of agreement:	Not specified.
Details:	Annual salary of kr 1,320,000 plus a cash bonus of up to 20% of base salary (subject to the satisfaction of performance criteria) to be reviewed annually by the Nomination and Remuneration Committee/Company. In addition, the Company will also pay the COO's occupational pension to Collectum under the terms of the benefit of ITP1. Prior to his resignation, Fabio Baglioni was entitled to participate in the Company's share and option plans. Please refer to the section titled 'Share-based compensation' for further details. Eight (8) week termination notice by either party however this notice period does not apply if the employment is terminated for serious and wilful misconduct or any conduct by Fabio Baglioni that amounts to fraud, theft, violence, harassment, gross negligence or any other action that may otherwise bring the Company into disrepute.

Share-based compensation

Share plan details

Prior to being listed on the ASX, the Company established a tax exempt employee share plan ('**Tax Exempt Plan**'). Under the Tax Exempt Plan, the Company may offer an eligible person restricted shares in the Company which are subject to a three year holding lock while the person remains employed by the Company. Offers of restricted shares under the Tax Exempt Plan not exceeding a total value of A$1,000 or such other amount as permitted under Subdivision 83A-B of the *Income Tax Assessment Act 1997* may be reduced from the assessable income of that eligible person for the income year in which the eligible person acquires those restricted shares. The objective of the Tax Exempt Plan is to align the interests of eligible Atomo employees and contractors with shareholders through the sharing of a personal interest in the future growth and development of the Company and to provide a means of attracting and retaining skilled and experienced eligible persons.

As at the date of this report, 320,000 share have been granted under the Tax Exempt Plan.

Option plan details

1. Pre-IPO option plan details

In prior financial years, the Company issued options to employees, Directors and key stakeholders to align the interests of those parties through the sharing of a personal interest in the future growth and development of the Company and to provide a means of attracting and retaining skilled and experienced eligible persons.

As at the date of this report, the Company had the following options outstanding under the pre-IPO option plans:

Expiry Date	Exercise price	Number of options
14 April 2022	$0.03	2,293,184
6 April 2022	$0.16	6,800,000
11 April 2023	$0.16	4,800,000
Total		**13,893,184**

All options were granted over unissued fully paid ordinary shares in the Company. Options granted carry no dividend or voting rights.

2. Post-IPO Option plan details

Shortly prior to being listed on the ASX, the Company established a new employee option plan to align the interests of eligible employees and Directors with shareholders through the sharing of a personal interest in the future growth and development of the Company and to provide a means of attracting and retaining skilled and experienced eligible persons.

Upon Atomo's admission to the official list of ASX, Atomo granted a total of 6,800,000 options under the post-IPO option plan to the four (4) executive KMPs exercisable at $0.25 within thirty six (36) months from the date of vesting. The options vest in three equal tranches in 12 months, 24 months and 36 months respectively, subject to the satisfaction of vesting conditions relating to KPIs determined by the Managing Director or in the case of the Managing Director, determined by the Board in consultation with the People, Culture and Remuneration Committee, as follows:

KPI 1: ROI Hurdle:

15% per annum calculated using the following formula:

Change in EBITDA year on year/amount invested in operating assets during the year.

KPI 2: Revenue Hurdle:

Tranche 1/FY21 – Revenue growth of 60%

Tranche 2/FY22 – Revenue growth of 40%

Tranche 3/FY23 – Revenue growth of 25%

As at the date of this report, the Company had on issue 3,466,667 options to KMPs under the post-IPO option plan.

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
John Kelly	666,667	14-Apr-20	14-Apr-22	14-Apr-25	$0.25	$0.131
John Kelly	666,666	14-Apr-20	14-Apr-23	14-Apr-26	$0.25	$0.141
William Souter	533,333	14-Apr-20	14-Apr-22	14-Apr-25	$0.25	$0.131
William Souter	533,334	14-Apr-20	14-Apr-23	14-Apr-26	$0.25	$0.141
Mark Smith	533,333	14-Apr-20	14-Apr-22	14-Apr-25	$0.25	$0.131
Mark Smith	533,334	14-Apr-20	14-Apr-23	14-Apr-26	$0.25	$0.141
Total	**3,466,667**					

In addition to the above, subsequent to 30 June 2021, the Board has exercised its discretion to allocate the following options to management as part of the Company's remuneration scheme to reward the diligent execution of the corporate strategy and to ensure retention of the key talent needed to deliver strategic outcome in the interest of shareholders:

John Kelly	333,333 options
William Souter	213,333 options
Mark Smith	213,333 options
Total	**759,999 options**

These options are exercisable at $0.25 per option and expire on 14 April 2024. In addition, these options are conditional upon the executive remaining employed by the Company and in the case of John Kelly, on Shareholder approval of the allocation.

All options were granted over unissued fully paid ordinary shares in the Company. Options granted carry no dividend or voting rights.

Additional disclosures relating to Key Management Personnel

Shareholding:

The number of shares in the Company held during the financial year by each Director and other members of the KMP of the Group, including their personally related parties, is set out below:

	Balance at the start of the year	Exercise of options	Balance at the end of the year
*Ordinary shares**			
John Keith	3,261,056	-	3,261,056
John Kelly	73,530,248	-	73,530,248
Curt LaBelle**	63,851,280	1,200,000	65,051,280
Paul Kasian	100,000	-	100,000
Connie Carnabuci	75,000	-	75,000
William Souter	250,000	-	250,000
Mark Smith	7,790,224	-	7,790,224
Fabio Baglioni^	-	-	-
Totals	**148,857,808**	**1,200,000**	**150,057,808**

* All share numbers are presented on a post share split basis.
** Includes shares held by Global Health Investment Fund LLC. Curt LaBelle is President at GHIF.
^ Resigned on 30 July 2021.

Option holding:

The number of options over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the consolidated entity, including their personally related parties, is set out below:

	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
*Options over ordinary shares **					
John Keith	3,600,000	-	-	-	3,600,000
John Kelly	2,000,000	-	-	(666,667)	1,333,333
Curt LaBelle ^	3,600,000	-	(1,200,000)	-	2,400,000
Paul Kasian	-	-	-	-	-
Connie Carnabuci	-	-	-	-	-
William Souter	1,600,000	-	-	(533,333)	1,066,667
Mark Smith	1,600,000	-	-	(533,333)	1,066,667
Fabio Baglioni	1,600,000	-	-	(1,600,000)	-
Totals	**14,000,000**	**-**	**(1,200,000)**	**(3,333,333)**	**9,466,667**

* All option numbers are presented on a post share split basis.
^ Includes options held by Global Health Investment Fund LLC. Curt LaBelle is President at GHIF.

Other transactions with key management personnel and their related parties:

Transactions between related parties are on normal commercial terms and conditions and no more favourable than those available to other parties, unless stated otherwise. The following transactions occurred with related parties:

	Consolidated	
	2021	2020
ID&E Pty Ltd, a company controlled by Mr George Sidis, previously a Non-Executive Director of the Company, provided the following services during the year whilst Mr George Sidis was a Non-Executive Director:		
Purchase of inventory	n/a – see note	1,383,733
Research and development	n/a – see note	1,524,861
Plant and equipment	n/a – see note	670,401
Other services	n/a – see note	560,306
Total	**n/a – see note**	**4,139,301**
At the end of the financial year, the following amounts were shown owing to related parties in trade and other payables:	n/a – see note	640,615

Note: As Mr George Sidis resigned as a Non-Executive Director of Atomo on 3 February 2020, no transactions between ID&E Pty Ltd and the Company are included in the table above with respect to the financial year to 30 June 2021 as he is no longer considered a related party.

Curt LaBelle is a Non-Executive Director of the Company and is also President of GHIF. GHIF is a substantial shareholder of the Company holding 11.4% of the issued capital of the Company as at 30 June 2021 (2020: 11.4%).

Statutory performance indicators

The Company aims to align its executive remuneration to its strategic and business objective and the creation of shareholder wealth. The table below shows measures of the Group's financial performance over the last three years (being the extent of available historic audited performance information) as required by the *Corporations Act 2001*. However, these are not necessarily consistent with the measures used in determining the variable amounts of remuneration to be awarded to KMPs. As a consequence, there may not always be a direct correlation between the statutory key performance measures and the variable remuneration awarded.

Measure	2021	2020	2019	2018
Loss for the year attributable to the Company ($)	(6,021,215)	(9,218,105)	(5,055,112)	(4,900,173)
Basic earnings per share (cents)	(1.07)	(2.59)	(1.81)	(1.86)
Dividend payments	-	-	-	-
Dividend payout ratio^	-	-	-	-
Increase/(decrease) in share price^^	(46%)	70%	-	-
Total KMP incentives as a percentage of profit/(loss) for the year	(27.6%)	(13.3%)	(9.3%)	(6.1%)

^ The dividend payout ratio is calculated on dividends paid and profit for the year.

^^ Atomo's shares first traded on the ASX on 16 April 2020 after successful completion of its IPO. Accordingly, no share price information has been provided prior to FY20. For FY20, the movement in shares price has been calculated as the difference between the IPO price (i.e. $0.20) and the closing price as at 30 June 2020 (i.e. $0.34).

This concludes the Remuneration Report, which has been audited.

Shares Under Option

Unissued ordinary shares of Atomo Diagnostics Limited under option as at the date of this report are as follows:

Expiry Date	Exercise Price	Number of Options
14 April 2022	$0.03	2,293,184
6 April 2022	$0.16	6,800,000
11 April 2023	$0.16	4,800,000
14 April 2024	$0.25	533,333
14 April 2025	$0.25	2,266,666
14 April 2026	$0.25	2,266,668
30 April 2024	$0.40	2,000,000
30 April 2024	$0.60	2,000,000
Total		**22,959,851**

In addition to the above, the Board has exercised its discretion to allocate the following new options to management as part of the Company's remuneration scheme to reward the diligent execution of the corporate strategy and to ensure retention of the key talent needed to deliver strategic outcome in the interest of shareholders:

John Kelly	333,333 options
William Souter	213,333 options
Mark Smith	213,333 options
Total	**759,999 options**

These options are exercisable at $0.25 per option and expire on 14 April 2024. In addition, these options are conditional upon the executive remaining employed by the Company and, in the case of John Kelly, on Shareholder approval of the allocation.

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

Shares issued on the Exercise of Options

The following ordinary shares of Atomo Diagnostics Limited were issued during the year ended 30 June 2021 and up to the date of this report on the exercise of options granted:

Date options granted	Exercise Price	Number of Options
24 November 2016	$0.16	4,000,000
6 April 2017	$0.16	2,400,000
15 September 2018	$0.16	800,000
Total		**7,200,000**

Indemnity and Insurance of Officers

The Company has indemnified the Directors and executives of the Group for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Group paid a premium in respect of a contract to insure the Directors and executives of the Group against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Indemnity and Insurance of the Auditor

The Group has not, during or since the end of the financial year end, indemnified or agreed to indemnify the auditor of the Group or any related entity against any liability incurred by the auditor.

During the financial year, the Group has not paid a premium in respect of a contract to insure the auditor of the Group or any related entity.

Proceedings on behalf of the Group

No person has applied to the Court under Section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Group, or to intervene in any proceedings to which the Group is a party for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings.

Non-audit services

Details of the amounts paid or payable to the Company's auditors for non-audit services provided during the financial year by the auditors are outlined in Note 19 to the Financial Statements.

The Directors are satisfied that the provision of non-audit services during the financial year, by the auditors (or by another person or firm on the auditors' behalf), is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

The Directors are of the opinion that the services as disclosed in Note 19 to the financial statements do not compromise the external auditors' independence requirements of the *Corporations Act 2001* for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditors; and
- none of the services undermine the general principles relating to auditor independence as set out in *APES 110 Code of Ethics for Professional Accountants* issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.

Officers of the Company who are former partners of the Company's Auditors

There are no officers of the Company who are former partners of BDO Australia.

Rounding of Amounts

The Group is of a kind referred to in *Corporations Instrument 2016/191*, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under Section 307C of the *Corporations Act 2001* is set out immediately after this Directors' Report.

Auditor

BDO Audit Pty Ltd continues in office in accordance with section 327 of the *Corporations Act 2001*.

This report is made in accordance with a resolution of Directors, pursuant to Section 298(2)(a) of the *Corporations Act 2001.*

On behalf of the Directors:

John Keith
Chair

27 August 2021
Sydney

07 FINANCIAL STATEMENTS

AUDITOR'S DECLARATION

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

DECLARATION OF INDEPENDENCE BY GARETH FEW TO THE DIRECTORS OF ATOMO DIAGNOSTICS LIMITED

As lead auditor of Atomo Diagnostics Limited for the year ended 30 June 2021, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Atomo Diagnostics Limited and the entities it controlled during the period.

Gareth Few

Gareth Few
Director

BDO Audit Pty Ltd

Sydney

27 August 2021

CONTENTS

Consolidated statement of profit or loss and other comprehensive income	37
Consolidated statement of financial position	38
Consolidated statement of changes in equity	39
Consolidated statement of cash flows	40
Notes to the financial statements	41
Directors' declaration	75
Independent auditor's report to members of Atomo Diagnostics Limited	77

General Information

The financial statements cover Atomo Diagnostics Limited as a consolidated entity consisting of Atomo Diagnostics Limited and the entities it controlled at the end of, or during, the year.

The financial statements are presented in Australian Dollars, which is Atomo Diagnostics Limited's functional and presentation currency.

Atomo Diagnostics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office
Level 2
701 - 703 Parramatta Road
Leichhardt NSW 2040

Principal place of business
Level 2
701 - 703 Parramatta Road
Leichhardt NSW 2040

A description of the nature of the Group's operations and its principal activities are included in the Directors' Report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 27 August 2021. The Directors have the power to amend and reissue the financial statements.

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 30 June 2021

	Note	Consolidated 2021	2020
Revenue	3	6,715,659	5,368,698
Cost of sales		(3,296,835)	(2,173,731)
Gross profit		**3,418,824**	**3,194,967**
Other income	3	814,226	844,518
Employee benefits expenses	4(a)	(3,813,094)	(2,972,709)
Foreign exchange gains/(losses)		(408,689)	(556,249)
Depreciation and amortisation	4(b)	(1,318,327)	(687,087)
Research and development expenses		(820,640)	(695,009)
Insurance		(349,621)	(86,981)
Inventory obsolescence expense		(332,332)	223,752
IPO expenses not taken up in equity		-	(883,866)
IT expenses		(214,862)	(146,958)
Occupancy expenses		(6,417)	(32,724)
Professional and consulting fees expense		(1,786,510)	(929,695)
Regulatory expenses		(397,854)	(293,594)
Travel expenses		12,573	(131,294)
Other expenses		(901,403)	(801,856)
Results from operating activities		**(6,104,126)**	**(3,954,785)**
Finance income	4(c)	90,696	21,858
Finance costs	4(c)	(7,785)	(5,285,178)
Net finance income/(cost)	**4(c)**	**82,911**	**(5,263,320)**
Loss before income tax		**(6,021,215)**	**(9,218,105)**
Income tax (expense)/benefit	5(a)	-	-
Loss for the year		**(6,021,215)**	**(9,218,105)**
Other comprehensive income and expenses			
Foreign currency translation reserve		223,652	(395,849)
Total comprehensive income for the period		**(5,797,563)**	**(9,613,954)**
Loss per share for profit attributable to owners of Atomo Diagnostics Limited			
		Cents	**Cents**
Basic earnings per share	27	(1.07)	(2.59)
Diluted earnings per share	27	(1.07)	(2.59)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Consolidated Statement of Financial Position
As at 30 June 2021

	Note	Consolidated 2021	2020
Assets			
Current assets			
Cash and cash equivalents	6(a)	17,946,517	27,103,838
Trade and other receivables	7	4,494,368	4,760,722
Inventories	8	3,042,245	1,209,676
Total current assets		**25,483,130**	**33,074,236**
Non-current assets			
Property, plant and equipment	9	3,687,705	1,452,598
Right-of-use assets	10	66,86	55,710
Intangible assets	11	3,001,106	1,518,334
Total non-current assets		**6,755,676**	**3,026,642**
Total assets		**32,238,806**	**36,100,878**
Liabilities			
Current liabilities			
Trade and other payables	12	1,783,958	1,296,904
Lease liabilities	13	67,589	47,866
Employee benefits	14	276,804	162,570
Total current liabilities		**2,128,351**	**1,507,340**
Non-current liabilities			
Lease liabilities	13	-	7,675
Employee benefits	14	23,074	105,023
Total non-current liabilities		**23,074**	**112,698**
Total Liabilities		**2,151,425**	**1,620,038**
Net assets		**30,087,381**	**34,480,840**
Equity			
Issued capital	15	67,921,661	66,514,571
Foreign currency translation reserve	16	(227,690)	(451,342)
Share based payment reserve	16	713,027	746,970
Accumulated losses		(38,319,617)	(32,329,359)
Total equity		**30,087,381**	**34,480,840**

The above statement of financial position should be read
in conjunction with the accompanying notes

Consolidated Statement of Changes in Equity

For the Year Ended 30 June 2021

	Issued Capital	Foreign Currency Translation Reserve	Share Based Payment Reserve	Accumulated Losses	Total Equity
Balance as at 1 July 2019	**17,110,055**	**(55,493)**	**585,105**	**(23,111,254)**	**(5,471,587)**
Loss for the year	-	-	-	(9,218,105)	(9,218,105)
Other comprehensive income	-	(395,849)	-	-	(395,849)
Total other comprehensive income for the year	-	(395,849)	-	(9,218,105)	(9,613,954)
Transactions with owners, recorded directly in equity					
Ordinary shares issued during the year	51,143,218	-	-	-	51,143,218
Capital raising costs	(2,245,060)	-	-	-	(2,245,060)
Equity-settled share-based payments	-	-	490,542	-	490,542
Exercise of options	506,358	-	(328,677)	-	177,681
Total transactions with owners	49,404,516	-	161,865	-	49,566,381
Balance as at 30 June 2020	**66,514,571**	**(451,342)**	**746,970**	**(32,329,359)**	**34,480,840**
Balance as at 1 July 2020	**66,514,571**	**(451,342)**	**746,970**	**(32,329,359)**	**34,480,840**
Loss for the year	-	-	-	(6,021,215)	(6,021,215)
Other comprehensive income	-	223,652	-	-	223,652
Total other comprehensive income for the year	-	223,652	-	(6,021,215)	(5,797,563)
Transactions with owners, recorded directly in equity					
Equity-settled share based payments	108,000	-	320,951	-	428,951
Exercise of options	1,311,482	-	(188,373)	-	1,123,109
Issue costs	(12,392)	-	-	-	(12,392)
Lapsed and Cancelled Options	-	-	(166,521)	30,957	(135,564)
Total transactions with owners	1,407,090	-	(33,943)	30,957	1,404,104
Balance as at 30 June 2021	**67,921,661**	**(227,690)**	**713,027**	**(38,319,617)**	**30,087,381**

The above statement of changes in equity should be read in conjunction with the accompanying notes

Consolidated Statement of Cash Flows

For the Year Ended 30 June 2021

	Note	Consolidated 2021	2020
Cash flows from operating activities			
Receipts from customers (inc. GST)		8,012,295	2,463,182
Payments to suppliers and employees (inc. GST)		(13,480,610)	(7,135,970)
Cash used in operations		(5,468,315)	(4,672,788)
Interest received		90,696	21,858
Interest paid		(5,430)	(1,498,548)
IPO costs not taken up in financing activities		-	(883,866)
R&D and other government incentives received		1,157,798	771,416
Net cash from/(used in) operating activities	**6(b)**	**(4,225,251)**	**(6,261,928)**
Cash flows from investing activities			
Payments for property, plant and equipment		(3,119,797)	(818,690)
Payments for intangible asset		(2,777,775)	(1,174,451)
Net cash from/(used in) investing activities		**(5,897,572)**	**(1,993,141)**
Cash flows from financing activities			
Repayment of borrowings		-	(9,342,512)
Repayment of leases		(113,347)	(79,169)
Net proceeds from issue of share capital		1,110,718	27,806,235
Net proceeds from issue of convertible notes		-	15,221,874
Net cash from/(used in) financing activities		**997,371**	**33,606,428**
Net increase/(decrease) in cash and cash equivalents		(9,125,452)	25,351,360
Cash and cash equivalents at the beginning of the financial year		27,103,838	1,855,706
Effect of exchange rate fluctuations on cash held		(31,869)	(103,228)
Cash and cash equivalents at the end of the financial year	**6(a)**	**17,946,517**	**27,103,838**

The above statement of cash flows should be read in conjunction with the accompanying notes

08 NOTES TO THE FINANCIAL STATEMENTS

NOTES TO THE FINANCIAL STATEMENTS

Note 1: Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('**AASB**') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The Directors have reviewed all of the new and revised accounting standards and interpretations issued by the Australian Accounting Standards Board for annual reporting periods beginning or after 1 July 2020. It has been determined that there is no impact, material or otherwise, of any other new or revised accounting standards and interpretations.

(b) Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('**AASB**') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('**IASB**').

Historical cost

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial instruments.

Reclassification of prior year amounts and balances:

In certain circumstances, prior year amounts and balances have been reclassified for comparability.

Critical accounting estimates:

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in Note 2.

(c) Parent entity

In accordance with the *Corporations Act 2001*, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in Note 24.

(d) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Atomo Diagnostics Limited ('**company**' or '**parent entity**') as at 30 June 2021 and the results of all subsidiaries for the year then ended. Atomo Diagnostics Limited and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated except where such amounts arise on monetary items that form part of the net investments in a foreign operation, in which case they are recognised in reserves. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the consolidated entity. Losses incurred by the consolidated entity are attributed to the non-controlling interest in full, even if that results in a deficit balance.

Where the consolidated entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The consolidated entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

(e) Operating segments

The Group manages its operations as a single business operation and there are no parts of the Group that qualify as operating segments under AASB 8 Operating Segments. The CEO (Chief Operating Decision Maker or '**CODM**') assesses the financial performance of the Group in an integrated basis only and accordingly, the Group is managed on the basis of a single segment, being medical device research and development. Information presented to the CODM on a monthly basis is categorised by type of expenditure.

(f) Foreign currency translation

The financial statements are presented in Australian dollars, which is Atomo Diagnostics Limited's functional and presentation currency.

Foreign currency transactions:
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign operations:
The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange

differences are recognised in other comprehensive income through the foreign currency reserve in equity.

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

(g) Revenue recognition

The consolidated entity recognises revenue as follows:

Revenue from contracts with customers and sale of goods
Revenue is measured based on the consideration specified in a contract with a customer. The Group recognises revenue when it transfers control over a good or service to a customer.

Customers obtain control of the HIV self-testing kits when the goods are ready and released by Quality Assurance (QA). It is then the responsibility of the customer to make the necessary arrangements for freight and the collection of goods from the Group's warehouse. Invoices are generated once the goods are released by QA and ready for collection by the customer. Invoices are usually payable within 30 to 75 days, dependent on the contracted agreement. The contracts do not allow the customers to return the goods as the testing kits have a set shelf-life and have gone through vigorous testing prior to delivery.

Where sales are made to customers on an OEM basis for use in their own test, including for COVID-19, revenue is recognised at the point transfer of control over those products at the warehouse delivery point.

Since none of the contracts permit the customer to return an item, revenue is recognised for all the goods once the goods have been released by QA and are available for collection at the Group's warehouse.

Interest
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.

(h) Income tax

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in other comprehensive income.

Current tax:
Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax liability arising from dividends.

Current tax assets and liabilities are offset only if certain criteria are met.

Deferred tax:
Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, or on taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognised for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date.

The measurement of deferred tax reflects the tax consequences that could follow the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if certain criteria are met.

R&D tax incentives:
R&D tax incentives received by the Group are recognised as other income over the periods necessary to match the benefit of the incentive with the costs for which it is intended to compensate ('**associated costs**'). Such periods will depend on whether the associated costs are capitalised or expensed as incurred.

Under this policy, for that portion of associated costs which are expensed during the period, the proportional incentive is recognised in other income in full during the same period. For that portion of associated costs which are capitalised during the period, the proportional incentive is initially offset against the capitalised associated costs and recognised against amortisation expense on a systematic basis matching the useful life of the capitalised asset.

(i) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

(j) Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

(k) Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days but certain customers have longer payment terms.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

(l) Inventories

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value on a 'first in first out' basis.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

(m) Property, plant and equipment

Recognition and measurement:
Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset.

If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Any gain and loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Subsequent expenditure:
Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Depreciation:
Depreciation is calculated based on the cost of property, plant and equipment less their estimated residual values using the straight-line basis over their estimated useful lives, and is generally recognised in profit or loss.

The estimated useful lives of property, plant and equipment are as follows:

Plant and equipment	2 - 5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

(n) Leases

The Group recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option.

The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Group recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

(o) Intangible assets

Recognition and measurement

Computer software:
Computer software comprises computer application system software and licenses. Costs incurred in developing products or systems and costs incurred in acquiring software and licenses that will contribute to future period financial benefits through revenue generation and/or cost reduction are capitalised to computer software. Costs capitalised include external direct costs of materials and services, direct payroll and payroll-related costs.

Patents, trademarks and licences
Other intangible assets, including patents, trademarks and licences that are acquired by the Group and have finite useful lives are measured at cost less any accumulated amortisation and impairment losses.

Capitalised development costs
Capitalised development costs relate to the Company's rapid test platforms and associated manufacturing assets and are capitalised only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognised in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment losses.

Expenditure on research activities is recognised in profit or loss as incurred.

Subsequent expenditure
Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

Amortisation
Amortisation is calculated based on the cost of intangible assets less their estimated residual values using the straight- line method over their estimated useful lives, and is generally recognised in profit or loss.

The estimated useful lives of intangible assets are as follows:

Patents and trademarks	10 - 20 years
Other intangibles	10 years
Capitalised development costs	10 years

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

(p) Impairment

Non-financial assets
At each reporting date, the Group reviews the carrying amounts of its non-financial assets (other than deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or cash generating units ('**CGUs**'). Goodwill arising from a business combination is allocated to CGUs or groups of CGUs that are expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its recoverable amount. Impairment losses are recognised in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amount of assets in the CGU on a pro rata basis. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

(q) Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(r) Financial instruments

Classification and measurement – non-derivative financial assets and financial liabilities:
The Group's management assessed which business models applied to the financial assets held by the Group and classified its financial instruments into the appropriate AASB 9 categories.

Financial assets classified as held-to-maturity and loans and receivables under AASB 139 that were measured at amortised cost continued to be measured at amortised cost under AASB 9 as they are held within a business model to collect contractual cash flows and these cash flows consist solely of payments of principal and interest on the principal amount outstanding.

In relation to the impairment of financial assets, AASB 9 requires an expected credit loss model as opposed to an incurred credit loss model under AASB 139. The expected credit loss model requires the Group to account for expected credit losses and changes in those expected credit losses at each reporting date to reflect changes in credit risk since initial recognition of the financial assets. Consequently, it is no longer necessary for a credit event to have occurred before credit losses are recognised.

The Group has one type of financial assets (trade and other receivables) that are subject to AASB 9's new expected credit loss model.

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

Apart from the above, the application of AASB 9 had no impact on the classification and measurement of the Group's financial assets and liabilities.

(s) Provisions

Provisions are recognised when the Group has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

(t) Employee benefits

Short-term employee benefits:
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits:
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense:
Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Share-based payments:
Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. Where early exercise has occurred, this cost is accelerated. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

(u) Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

(v) Issued capital

Ordinary shares, Class B shares and Ord+ shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

(w) Dividends

Dividends are recognised when declared during the financial year and no longer at the discretion of the Company.

(x) Earnings per share

Basic earnings per share:
Basic earnings per share is calculated by dividing the profit attributable to the owners of Atomo Diagnostics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share:
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

(y) Goods and Services Tax (‘GST’) and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

(z) Rounding of amounts

The Company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to ‘rounding-off’. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Note 2: Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Revenue recognition:
When recognising revenue in relation to the sale of goods to customers, the key performance obligation is considered to be the point the customer obtains control of the goods as outlined in the arrangement.

Share-based payment transactions:
The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value of options is determined by using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted and includes assumptions which require judgement.

The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Allowance for expected credit losses:
The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Write-down of inventories:
Any write-down of inventories requires a degree of estimation and judgement. The level of the write-down is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Fair value measurement hierarchy:
The Group is required to classify all assets and liabilities, measured at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

The fair value of assets and liabilities classified as level 3 is determined by the use of valuation models. These include discounted cash flow analysis or the use of observable inputs that require significant adjustments based on unobservable inputs.

Estimation of useful lives of assets:
The Group determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Impairment of intangible assets:
The Group tests intangible assets for impairment for each reporting period or more frequently if events or changes in circumstances indicate it has suffered any impairment, in accordance with the accounting policy stated in Note 3(o). The recoverable amount of a cash generating unit ('**CGU**') is determined based on value-in-use calculations whereby cash flows are projected and extrapolated over a five year period with growth rates that do not exceed the long-term average growth rate for the market in which the Group operates. The discount rate used reflects the Group's pre-tax weighted average cost of capital.

Note 3: Revenue and other income

	Consolidated	
	2021	2020
Revenue:		
Revenue from sale of goods		
COVID-19	3,664,613	3,397,307
HIV	1,082,528	1,184,743
Other OEM	1,942,878	522,626
Other	25,640	264,022
	6,715,659	5,368,698
Other income:		
R&D tax rebate	754,676	807,018
R&D tax rebate overprovisioned in prior year	(161,808)	-
COVID-19 Government grants	108,588	-
Other income	112,770	37,500
	814,226	844,518
Total revenue and other income	**7,529,885**	**6,213,216**

Note 4: Expenses

	Consolidated 2021	2020
Profit/(loss) before income tax from continuing operations includes the following specific expenses:		
(a) Employee benefits expense		
Salaries, wages and Directors' fees	3,141,315	2,118,598
Contributions to superannuation	267,779	161,061
Equity-settled share-based payments	293,386	616,930
Other employment related expenses	110,614	76,120
	3,813,094	2,972,709
(b) Depreciation and amortisation expense		
Depreciation expense (Note 9)	884,690	519,388
Amortisation expense (Note 11)	319,396	90,090
Right-of-use assets (Note 10)	114,241	77,609
	1,318,327	687,087
(c) Net finance income/(cost)		
Interest income	90,697	21,858
Cash interest expense	(2,880)	(1,207,464)
Effective Interest Expense	(4,906)	(7,055,755)
Borrowing Costs	-	(826,397)
Fair value gain/(loss) on financial liabilities	-	3,804,438
	82,911	(5,263,320)

Note 5: Income tax

(a) Income tax benefit

Income tax benefit comprises current and deferred tax expense and is recognised in profit or loss, except to the extent that it relates to a business combination or items recognised directly in equity or other comprehensive income. The components of income tax benefit comprise:

	Consolidated 2021	2020
Current tax	-	-
Deferred tax	-	-
Total income tax benefit	**-**	**-**

Note 5: Income tax (continued)

The prima facie tax on profit before income tax is reconciled to the income tax benefit as follows:

	Consolidated	
	2021	2020
Loss before income tax	(6,021,215)	(9,218,105)
Tax using the Company's domestic Australian tax rate of 26.0% (2020: 27.5%)	1,444,097	2,534,979
Permanent and temporary differences	(1,093,633)	(1,783,117)
Other	-	50,813
Tax losses not brought to account	(350,464)	(802,675)
Total income tax benefit	**-**	**-**

(b) Deferred tax assets and liabilities

Due to the uncertainty of the Group generating sufficient taxable income to offset tax losses carried forward, the future tax benefits of these losses, to the extent that they do not set off temporary differences that have resulted in deferred tax liabilities, has not been brought to account in these financial statements.

Net tax effect of carried forward losses not brought to account	2,804,480	2,547,090

Note 6: Current assets – cash and cash equivalents

	Consolidated	
	2021	2020
(a) Cash and cash equivalents in statement of cash flows		
Cash at bank	17,946,517	27,103,838
	17,946,517	27,103,838
(b) Reconciliation of cash flows from operating activities		
Loss for the year	(6,021,215)	(9,218,105)
Adjustments for:		
Depreciation and amortisation	1,318,327	687,087
Unrealised currency translation movements	255,522	556,249
Equity-settled share-based payment transactions	293,386	616,930
Fair value (gain)/loss on financial liabilities	-	(3,804,438)
Finance costs	-	7,882,152
	1,867,235	5,937,980
Operating profit before changes in working capital and provisions	(4,153,980)	(3,280,125)
Changes in working capital and provisions:		
Change in trade and other receivables	1,369,989	(2,941,119)
Change in trade and other payables	359,024	247,027
Change in inventories	(1,832,569)	(421,958)
Change in employee benefits	32,285	134,246
	(71,271)	(2,981,804)
Net cash from operating activities	**(4,225,251)**	**(6,261,928)**

Note 7: Current assets – trade and other receivables

	Consolidated	
	2021	2020
Receivables from trade customers	1,934,717	3,003,406
Expected credit loss/bad debt provision	(70,433)	-
R&D Tax Rebate Receivable	1,823,828	1,273,201
Other receivables	806,256	484,115
	4,494,368	4,760,722

Allowance for expected credit losses:
The Group monitors its level of debt recovery at each reporting date (including interim reporting dates) in order to assess for any changes in the probability of customers' ability to pay, including due to external factors such as the COVID-19 pandemic.

The ageing of receivables from trade customers and allowance for expected credit losses provide for above are as follows:

Consolidated – 2021	0 to 30 Days	31 to 60 Days	61 to 90 Days	91 to 120 Days	121+ Days	Total
Trade receivables	678,10	346,824	168,189	684,297	57,299	1,934,717
Allowance for expected credit losses	-	(3,468)	-	(41,058)	(25,907)	(70,433)
Carrying value of trade receivables before additional bad debt provisions	678,108	343,356	168,189	643,239	31,392	1,864,284

Note 8: Current assets – inventories

	Consolidated	
	2021	2020
Raw material	1,809,489	876,105
Raw materials provision	(8,247)	(24,764)
Work in progress	130,498	22,498
Finished goods	1,309,497	335,837
Finished goods provision	(198,992)	-
	3,042,245	1,209,676

Note 9: Non-current assets – property, plant and equipment

	Consolidated	
	2021	2020
Plant and equipment – at cost	6,170,381	3,050,584
Less: Accumulated depreciation	(2,482,676)	(1,597,986)
Total plant and equipment	3,687,705	1,452,598
Total property, plant and equipment	**3,687,705**	**1,452,598**

Note 9: Non-current assets – property, plant and equipment (continued)

Reconciliations:

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Plant and equipment	Total
Balance at 1 July 2019	1,153,29	1,153,296
Additions	818,690	818,690
Depreciation expense	(519,388)	(519,388)
Balance at 30 June 2020	**1,452,598**	**1,452,598**
Balance at 1 July 2020	1,452,598	1,452,598
Additions	3,119,797	3,119,797
Depreciation expense	(884,690)	(884,690)
Balance at 31 June 2021	**3,687,705**	**3,687,705**

Note 10: Non-current assets – right-of-use assets

	Consolidated	
	2021	2020
Land and buildings – right-of-use (Note 13)	68,136	118,727
Less: Accumulated depreciation (Note 13)	(8,517)	(73,887)
	59,619	44,840
Plant and equipment – right-of-use (Note 13)	14,493	14,493
Less: Accumulated depreciation (Note 13)	(7,247)	(3,623)
	7,246	10,870
Total right-of-use assets	**66,865**	**55,710**

Additions to the right-of-use assets during the year were $Nil.

The Group leases land and buildings for its offices in Sydney Australia and warehouse in South Africa under agreements of between one (1) to two (2) years with, in some cases, options to extend. The Group also leases a single piece of office equipment under a five (5) year agreement.

The Company entered into a new lease prior to 30 June 2021 but which does not commence until September 2021. Upon commencement, a lease liablity in the amount of $320,711 will be recognised along with a corresponding right-of-use asset. Refer to Note 22 for further details.

Note 11: Non-current assets – intangible assets

	Consolidated 2021	Consolidated 2020
Patents and trademarks – at cost	1,555,258	1,449,224
Less: accumulated amortisation	(598,715)	(536,164)
Total patents and trademarks	956,543	913,060
Product development assets – at cost	2,317,974	621,840
Less: accumulated amortisation	(291,428)	(36,845)
Total product development assets	2,026,546	584,995
Other intangibles – at cost	91,429	91,429
Less: accumulated amortisation	(73,412)	(71,150)
Total other intangibles	18,017	20,279
Total intangible assets	**3,001,106**	**1,518,334**

Reconciliations:

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Patents and trademarks	Product development costs	Other intangibles	Total
Balance at 1 July 2019	868,208	-	32,188	900,396
Additions	102,215	1,072,234	-	1,174,449
Amortisation expense	(57,363)	(36,846)	(11,909)	(106,118)
Capitalisation of R&D rebate	-	(466,421)	-	(466,421)
Capitalised R&D rebate recognised in profit and loss	-	16,028	-	16,028
Balance at 30 June 2020	**913,060**	**584,995**	**20,279**	**1,518,334**
Balance at 1 July 2020	913,060	584,995	20,279	1,518,334
Additions	106,034	2,671,740	-	2,777,774
Amortisation expense	(62,551)	(254,583)	(2,262	(319,396)
Capitalisation of R&D rebate	-	(1,162,207)	-	(1,162,207)
Reversal of over-accrued capitalised R&D rebate from prior year	-	93,546	-	93,546
Capitalised R&D rebate recognised as income	-	93,055	-	93,055
Balance at 30 June 2021	**956,543**	**2,026,546**	**18,017**	**3,001,106**

Note 12: Current liabilities – trade and other payables

	Consolidated	
	2021	2020
Trade payables	654,502	930,035
Accrued expenses	825,188	302,350
Other payables	304,268	64,519
	1,783,958	1,296,904

All amounts are short term and the carrying values are considered to be a reasonable approximation of fair value.

Note 13: Lease liabilities

	Consolidated	
	2021	2020
Current:		
Lease liabilities (Note 10)	67,589	47,866
	67,589	47,866
Non-current:		
Lease liabilities (Note 10)	-	7,675
	-	7,675
Total lease liabilities	**67,589**	**55,541**

Note 14: Employee benefits

	Consolidated	
	2021	2020
Current:		
Liability for annual leave	204,561	162,570
Liability for long service leave	72,243	-
	276,804	162,570
Non-current:		
Liability for long service leave	23,074	105,023
	23,074	105,023
Total employee benefits	**299,878**	**267,593**

The current provision for employee benefits includes all unconditional entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The entire amount is presented as current since the consolidated entity does not have an unconditional right to defer settlement.

Note 15: Equity – issued capital

Movements in ordinary share capital:

	Ordinary Shares		Class B Shares		Ord+ Shares		Total	
	2021	2020	2021	2020	2021	2020	2021	2020
Number of shares:								
On issue as at 1 July	561,077,807	28,458,647	-	5,979,846	-	1,953,852	561,077,807	36,392,345
Issue of Shares Under Employee Share Plan	320,000	-	-	-	-	-	320,000	-
Impact of 1:8 share split	-	199,210,529	-	41,858,922	-	13,676,964	-	254,746,415
Conversion of Ord+ shares	-	15,630,816	-	-	-	(15,630,816)	-	-
Conversion of Class B shares	-	47,838,768	-	(47,838,768)	-	-	-	
Exercise of Options	7,200,000	8,768,491	-	-	-	-	7,200,000	8,768,491
Exercise of GHIF Warrants	-	10,868,183	-	-	-	-	-	10,868,183
Conversion of Converting Notes	-	100,302,363	-	-	-	-		100,302,363
Shares issued at IPO	-	150,000,010	-	-	-	-	-	150,000,010
On issue as at 30 June	**568,597,807**	**561,077,807**	**-**	**-**	**-**	**-**	**568,597,807**	**561,077,807**
Value ($):								
On issue as at 1 July	66,514,571	8,630,940	-	6,036,800	-	2,442,315	66,514,571	17,110,055
Issue of Shares Under Employee Share Plan	108,000	-	-	-	-	-	108,000	-
Impact of 1:8 share split	-	-	-	-	-	-	-	-
Conversion of Ord+ shares	-	2,442,315	-	-	-	(2,442,315)	-	-
Conversion of Class B shares	-	6,036,800	-	(6,036,800)	-	-	-	-
Exercise of Options	1,311,482	506,358	-	-	-	-	1,311,482	506,358
Exercise of GHIF Warrants	-	1,082,743	-	-	-	-	-	1,082,743
Conversion of Converting Notes	-	20,060,473	-	-	-	-	-	20,060,473
Shares issued at IPO	-	30,000,002	-	-	-	-	-	30,000,002
Costs Associated with the Issues of Shares	(12,392)	(2,245,060)	-	-	-	-	(12,392)	(2,245,060)
On issue as at 30 June	**67,921,661**	**66,514,571**	**-**	**-**	**-**	**-**	**67,921,661**	**66,514,571**

Note 15: Equity – issued capital (continued)

Ordinary shares:

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

B Class shares:

During the year ended 30 June 2020 and concurrently with the IPO, 47,838,768 B Class shares (post share split) were converted into ordinary shares on a 1:1 basis pursuant to approval by shareholders on 19 December 2019. As at 30 June 2020, no B Class shares remained on issue.

B Class shares had the same rights as ordinary voting shares and were subject to the terms of the Investors Agreements and the Company's Constitution, save for the special terms that attached to B Class shares which were as follows:

i. upon winding-up of the Company, each B Class share would convert into 1.2 ordinary shares;

ii. in the event of sale of all the shares in the Company for a total consideration of not more than US$20,000,000, each B Class share would convert into 1.2 ordinary shares with effect immediately prior to the sale. If the sale price was more than US$20,000,000 then the B Class shares would convert into ordinary shares on a 1 for 1 basis;

iii. in the event of listing of the Company's shares on a securities exchange at an initial price implying a total company market capitalisation of not more than US$20,000,000, each B Class share would convert into 1.2 ordinary shares with effect immediately prior to the sale. If the initial price implies a total company market capitalisation of more than US$20,000,000 then the B class shares would convert into ordinary shares 1 for 1; and

iv. for any period when a B Class shareholder holds a minimum of 2 million shares in the Company (whether B class or ordinary shares), the shareholder would have the right to appoint a Director to the Board.

Ord+ shares:

During the year ended 30 June 2020, 15,630,816 Ord+ shares (post share split) were converted into ordinary shares on a 1:1 basis pursuant to approval by shareholders on 19 December 2019. As at 30 June 2020, no Ord+ shares remained on issue.

Ord+ shares had the same rights as ordinary voting shares and were subject to the terms of the Investors' Agreements and the Company's Constitution, save for the special terms that attached to Ord+ shares which were as follows:

Note 15: Equity – issued capital (continued)

i. the shares were issued with an accompanying entitlement to bonus shares which were to be issued in the event that a subsequent capital activity occurred at a price less than $1.50 per ordinary share; and

ii. the bonus shares entitlement applied in respect of the next capital activity that had one of the following characteristics:

a. if the Company issued further ordinary shares for a price less than $1.50 ($0.1875 on a post share split basis) per share (other than in response to the exercise of existing share options or warrants), with an aggregate issue offer value in excess of $3,000,000; or

b. if an agreement was made by which all of the ordinary shares in the Company were to be sold at an average price of less that $1.50 ($0.1875 on a post share split basis) per share.

Capital risk management:

The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders, maintain sufficient financial flexibility to pursue its growth objectives and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Group may take one of several actions which may include the issue of new shares, the payment of dividends, a return capital to shareholders, or sell assets to reduce debt. The Group is not actively pursuing or consideraing any of these options at the time of this report.

The Company may look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment. The Group is not actively pursuing additional investments in the short term as it continues to grow its existing businesses.

The Group currently has no debt and is not subject to any finance arrangement covenants.

Note 16: Equity – reserves

	Consolidated	
	2021	2020
Foreign currency translation reserve	(227,690)	(451,342)
Share based payment reserve	713,027	746,970
	485,337	295,628

Foreign currency translation reserve:

This reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars and the effect of permanent loans with foreign operations within the Group.

Note 16: Equity – reserves (continued)

Share based payment reserve:

This reserve is used to recognise the fair value of equity-settled share-based payments where they relate to yet-to-be exercised options.

Movements in reserves:

Movements in each class of reserve during the current and previous financial year are set out below:

Consolidated	Foreign currency	Share based payment	Total
Balance at 1 July 2019	(55,493)	585,105	529,612
Equity-settled share-based payments	-	490,542	490,542
Exercise of options	-	(328,677)	(328,677)
Foreign currency translation	(395,849)	-	(395,849)
Balance at 30 June 2020	**(451,342)**	**746,970**	**295,628**
Balance at 1 July 2020	(451,342)	746,970	295,628
Equity-settled share-based payments	-	320,951	320,951
Exercise of options	-	(188,373)	(188,373)
Lapsed and Cancelled Options	-	(166,521)	(166,521)
Foreign currency translation	223,652	-	223,652
Balance at 30 June 2021	**(227,690)**	**713,027**	**485,337**

Note 17: Equity – dividends

No dividends were paid or declared during the financial year (2020: Nil).

Franking credits:

	Consolidated	
	2021	2020
Franking credits available for subsequent financial years	-	-

Note 18: Financial risk management

Financial risk management objectives

The Group's activities expose it to a variety of financial risks including market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The Group's overall risk management objectives seek to minimise potential adverse effects on the financial performance of the Group. The Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, foreign exchange and other price risks, ageing analysis for credit risk and beta analysis in respect of investment portfolios to determine market risk.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance identifies and evaluates financial risks within the Group. Finance reports to the Board on a monthly basis.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates and interest rates. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

Foreign currency risk

The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The carrying amount of the consolidated entity's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	Assets		Liabilities	
Consolidated	2021	2020	2021	2020
US Dollars	2,693,426	3,564,797	240,296	144,256
British Pounds	4,455	15,990	11,163	5,212
South African Rand	491,346	203,623	33,990	25,719
Japanese Yen	-	-	-	3,308
EURO	-	-	-	3,215
Swedish Krona Sek	-	-	-	3,618
Swiss Franc	-	-	14,420	-
	3,189,227	**3,784,410**	**299,869**	**185,328**

Note 18: Financial risk management (continued)

Reasonably possible movements in the Australian dollar against all other currencies as at 30 June 2021 would have affected the measurement of financial instruments denominated in a foreign currency and affected profit or loss and equity by the amounts shown below. This analysis assumes that all other variables remain constant and ignores any impact of forecast sales and purchases:

	Profit Before Tax		Equity	
Consolidated	**2021**	**2020**	**2021**	**2020**
AUD Strengthening by 10%	(262,669)	(327,189)	(262,669)	(327,189)
AUD Weakening by 10%	321,040	399,898	321,040	399,898

Price risk

The Group is not exposed to any significant price risk.

Interest rate risk

As at 30 June 2021, the Group was not exposed to any significant interest rate risk. There is minimal exposure to the impact of adverse changes in benchmark interest rates.

The Group was exposed to variable interest rate risks on cash and short-term deposits. A reasonably possible change of 100 basis points in interest rates during the year would have increased or decreased profit before tax by $198,794 (2020: $100,041). This analysis assumes that all other variables remain constant.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has a code of credit, including undertaking customer due diligence, confirming references and setting appropriate credit limits as appropriate. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements.

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year.

Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Note 18: Financial risk management (continued)

Financing arrangements:
The Group has no used or unused financing facilities in place as at 30 June 2021 (2020: Nil).

Remaining contractual maturities:
The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

Consolidated – 2021	Weighted average interest rate	1 year or less	Between 1 and 2 years	Between 2 and 5 years	Over 5 years	Remaining contractual maturities
Non-derivatives						
Non-interest bearing						
Trade payables	-	654,502	-	-	-	-
Other payables	-	1,129,456	-	-	-	-
Interest-bearing						
Lease liabilities	7.00%	67,589	-	-	-	-
Total non-derivatives		**1,851,547**	**-**	**-**	**-**	**-**

Consolidated – 2020	Weighted average interest rate	1 year or less	Between 1 and 2 years	Between 2 and 5 years	Over 5 years	Remaining contractual maturities
Non-derivatives						
Non-interest bearing						
Trade payables	-	930,035	-	-	-	-
Other payables	-	366,869	-	-	-	-
Interest-bearing						
Lease liabilities	7.00%	47,866	7,675	-	-	-
Total non-derivatives		**1,344,770**	**7,675**	**-**	**-**	**-**

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Note 19: Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by the Company's auditors, their network firms and unrelated firms:

	Consolidated	
	2021	2020
Audit and assurance services:		
KMPG Australia:		
Audit of financial statements	-	108,790
BDO Australia:		
Audit of financial statements	81,000	46,000
Total audit and assurance services	81,000	154,790
Other services:		
KMPG Australia:		
Tax advisory services	-	23,140
BDO Australia:		
Independent limited assurance services in relation to the prospectus	-	164,897
Tax advisory services	30,000	-
Other services	11,442	-
Total other services	41,442	188,037
Total auditors' remuneration	**122,442**	**342,827**

Note 20: Contingent assets

There were no contingent assets as at 30 June 2021.

Note 21: Contingent liabilities

There were no contingent liabilities as at 30 June 2021.

Note 22: Commitments

	Consolidated	
	2021	2020
Capital commitments		
Committed at the reporting date but not recognised as liabilities payable: Plant and equipment and intangibles	2,189,174	2,668,969
Other commitments		
Inventory	1,037,221	2,463,221
Lease liabilities	320,711	-
Total commitments	**3,547,106**	**5,132,190**

Capital commitments relate to the expansion of manufacturing capacity to support growth. Plant and equipment to be purchased includes additional tooling, assembly lines and associated machinery to support increased production of Atomo's suite of devices.

Inventory commitments relate to volumes of devices committed to be purchased throughout the year for sale to customers.

Lease liabilities relate to a new lease which the Company entered into prior to 30 June 2021 but which does not commence until September 2021. Upon commencement, a lease liablity in the amount of $320,711 will be recognised along with a corresponding right-of-use asset.

Note 23: Related party transactions

Parent entity:

Atomo Diagnostics Limited is the Parent Entity.

Subsidiaries:

Interests in subsidiaries are set out in Note 25.

Key management personnel compensation:

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:

	Consolidated	
	2021	2020
Short-term employee benefits	1,655,322	981,089
Post-employment benefits	68,538	55,928
Long-term benefits	7,881	26,356
Share-based payments	(67,169)	164,302
Total key management personnel compensation	**1,664,572**	**1,227,675**

Further details relating to key management personnel compensation are set out in the remuneration report included in the Directors' report.

Transactions with other related parties:

Transactions between related parties are on normal commercial terms and conditions and no more favourable than those available to other parties, unless stated otherwise. The following transactions occurred with related parties:

	Consolidated	
	2021	2020
ID&E Pty Ltd, a company controlled by Mr George Sidis, previously a Non-Executive Director of the Company, provided the following services during the year whilst Mr George Sidis was a Non-Executive Director:		
Purchase of inventory	n/a – see note	1,383,733
Reseach and development	n/a – see note	1,524,861
Plant and equipment	n/a – see note	670,401
Other services	n/a – see note	560,306
Total	**n/a – see note**	**4,139,301**
At the end of the financial year, the following amounts were shown owing to related parties in trade and other payables	n/a – see note	640,615

Note: As Mr George Sidis resigned as a Non-Executive Director of Atomo on 3 February 2020, no transactions between ID&E Pty Ltd and the Company are included in the table above with respect to the financial year to 30 June 2021 as he is no longer considered a related party.

Key management personnel transactions:

Directors and other key management personnel hold 26.4% of the issued capital of the Company as at 30 June 2021 (30 June 2020: 28.2%).

Note 24: Parent entity information

Set out below is the supplementary information about the Parent Entity.

	Parent	
	2021	2020
Statement of profit or loss and other comprehensive income		
Loss for the year	(11,982,954)	(9,392,919)
Other comprehensive income	-	-
Total comprehensive income	**(11,982,954)**	**(9,392,919)**

	Parent	
	2021	2020
Statement of financial position		
Assets		
Total current assets	24,096,206	38,388,486
Total non-current assets	7,031,323	2,787,862
Total assets	**31,127,529**	**41,176,348**
Liabilities		
Total current liabilities	2,059,279	1,447,299
Total non-current liabilities	23,074	105,023
Total liabilities	**2,082,353**	**1,552,322**
Total net assets	**29,045,176**	**39,624,026**
Equity		
Share capital	67,921,661	66,514,571
Share based payment reserve	713,027	746,970
Retained earnings	(39,589,512)	(27,637,515)
Total equity	**29,045,176**	**39,624,026**

Guarantees entered into by the Parent Entity in relation to the debts of its subsidiaries
None.

Contingent liabilities
There were no contingent liabilities attributed to the Parent Entity as at 30 June 2021 (2020: Nil).

Commitments

	Consolidated	
	2021	2020
Capital commitments		
Committed at the reporting date but not recognised as liabilities payable:		
Plant and equipment and intangibles	2,106,035	2,668,969
Other commitments		
Inventory	1,037,221	2,463,221
Lease liabilities	320,711	-
Total commitments	**3,463,967**	**5,132,190**

Note 24: Parent entity information (continued)

Capital commitments relate to the expansion of manufacturing capacity to support growth. Plant and equipment to be purchased includes additional tooling, assembly lines and associated machinery to support increased production of Atomo's suite of devices.

Inventory commitments relate to volumes of devices committed to be purchased throughout the year for sale to customers.

Lease liabilities relate to a new lease which the Company entered into prior to 30 June 2021 but which does not commence until September 2021. Upon commencement, a lease liablity in the amount of $320,711 will be recognised along with a corresponding right-of-use asset.

Significant accounting policies
The accounting policies of the Parent Entity are consistent with those of the consolidated entity, as disclosed in Note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the Parent Entity.
- Dividends received from subsidiaries are recognised as other income by the Parent Entity and its receipt may be an indicator of an impairment of the investment.

Note 25: Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries and branch operations in accordance with the accounting policy described in Note 1:

Name	Principal place of business/ Country of incorporation	Ownership interest 2021 %	Ownership interest 2020 %
Parent entity:			
Atomo Diagnostics Limited	Australia		
Subsidiaries:			
Atomo Australia Pty Limited	Australia	100%	100%
Atomo Limited	United Kingdom	100%	100%
Branch operations:			
Atomo South Africa (operating branch of Atomo Australia Pty Limited)	South Africa	100%	100%

Note 26: Events after the reporting period

- Mr Fabio Baglioni, a former executive of the Group, resigned on 30 July 2021. Consequently, 1,600,000 options issued to Mr Baglioni under the Company's Post-IPO option plan, lapsed.
- 1,733,333 options issued to executives under the Company's Post-IPO options plan lapsed as the KPIs applicable to the options were not satisfied with respect to the year ended 30 June 2021.
- The Board has exercised its discretion to allocate 759,999 new options to executives under the Company's post-IPO option plan to reward the diligent execution of the corporate strategy and to ensure retention of the key talent needed to deliver strategic outcomes in the interest of shareholders.

No other matter or circumstance has arisen since 30 June 2021 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 27: Earnings per share

	Consolidated	
	2021	2020
Loss after income tax attributable to the owners of Atomo Diagnostics Limited	(6,021,215)	(9,218,105)
Loss after income tax attributable to the owners of Atomo Diagnostics Limited used in calculating diluted earnings per share	(6,021,215)	(9,218,105)
	Cents	**Cents**
Basic earnings per share	(1.07)	(2.59)
Diluted earnings per share	(1.07)	(2.59)
	Number	**Number**
Weighted average number of ordinary shares:		
Weighted average number of ordinary shares used in calculating basic earnings per share	564,334,355	355,359,884
Adjustments for calculation of diluted earnings per share:		
No adjustments given that in a loss situation, this would be anti-dilutive	-	-
Weighted average number of ordinary shares used in calculating diluted earnings per share	564,334,355	355,359,884

The weighted average number of ordinary shares used in the calculation for earnings per share for 2020 has been amended to reflect the 1:8 share split which took place on 21 February 2020.

Note 28: Share-based payments

Set out below are summaries of options granted:

2021

Grant date	Note	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
20/04/2012	28(a)	14/04/2022	$0.03	-	-	-	-	-
21/11/2012	28(a)	14/04/2022	$0.03	2,293,184	-	-	-	2,293,184
27/06/2014	28(a)	14/04/2022	$0.08	-	-	-	-	-
24/11/2016	28(a)	24/11/2020	$0.16	5,000,000	-	(4,000,000)	(1,000,000)	-
6/04/2017	28(a)	6/04/2021	$0.16	3,600,000	-	(2,400,000)	(1,200,000)	-
6/04/2018	28(a)	6/04/2022	$0.16	6,800,000	-	-	-	6,800,000
15/09/2018	28(a)	15/09/2022	$0.16	800,000	-	(800,000)	-	-
11/04/2019	28(a)	11/04/2023	$0.16	4,800,000	-	-	-	4,800,000
14/04/2020	28(b)	14/04/2024	$0.25	2,799,999	-	-	(2,266,666)	533,333
14/04/2020	28(b)	14/04/2025	$0.25	2,799,999	-	-	(533,333)	2,266,666
14/04/2020	28(b)	14/04/2026	$0.25	2,800,002	-	-	(533,334)	2,266,668
31/05/2021	28(c)	30/04/2024	$0.40	-	2,000,000	-	-	2,000,000
31/05/2021	28(c)	30/04/2024	$0.60	-	2,000,000	-	-	2,000,000
				31,693,184	**4,000,000**	**(7,200,000)**	**(5,533,333)**	**22,959,851**
Weighted average exercise price				$0.17	$0.50	$0.16	$0.21	$0.23
Weighted average remaining contractual life (years)								2.1

2020

Grant date	Note	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
20/04/2012	28(a)	14/04/2022	$0.03	480,000	-	(480,000)	-	-
21/11/2012	28(a)	14/04/2022	$0.03	8,862,624	-	(6,569,440)	-	2,293,184
27/06/2014	28(a)	14/04/2022	$0.08	800,000	-	(800,000)	-	-
24/11/2016	28(a)	24/11/2020	$0.16	10,400,000	-	(5,400,000)	-	5,000,000
6/04/2017	28(a)	6/04/2021	$0.16	4,800,000	-	(1,200,000)	-	3,600,000
6/04/2018	28(a)	6/04/2022	$0.16	9,200,000	-	(2,400,000)	-	6,800,000
15/09/2018	28(a)	15/09/2022	$0.16	2,000,000	-	(1,200,000)	-	800,000
11/04/2019	28(a)	11/04/2023	$0.16	4,800,000	-	-	-	4,800,000
14/04/2020	28(b)	14/04/2024	$0.25	-	2,799,999	-	-	2,799,999
14/04/2020	28(b)	14/04/2025	$0.25	-	2,799,999	-	-	2,799,999
14/04/2020	28(b)	14/04/2026	$0.25	-	2,800,002	-	-	2,800,002
				41,342,624	**8,400,000**	**(18,049,440)**	**-**	**31,693,184**
Weighted average exercise price				$0.13	$0.25	$0.11	n/a	$0.17
Weighted average remaining contractual life (years)								2.4

(a) Pre-IPO Options

In prior financial years, the Company issued options to employees, Directors and key stakeholders to align the interests of those parties through the sharing of a personal interest in the future growth and development of the Company and to provide a means of attracting and retaining skille and experienced eligible persons.

All options were granted over unissued fully paid ordinary shares in the Company. Options granted carry no dividend or voting rights.

(b) Post-IPO Options

Shortly prior to being listed on the ASX, the Company established a new employee option plan to align the interests of eligible employees and Directors with shareholders through the sharing of a personal interest in the future growth and development of the Company and to provide a means of attracting and retaining skilled and experienced eligible persons.

Upon Atomo's admission to the official list of ASX, Atomo granted a total of 8,400,000 options under the post-IPO option plan to the four (4) executive KMPs exercisable at $0.25 within thirty six (36) months from the date of vesting. The options vest in three equal tranches in 12 months, 24 months and 36 months respectively, subject to the satisfaction of vesting conditions relating to KPIs determined by the Managing Director or in the case of the Managing Director, determined by the Board in consultation with the People, Culture and Remuneration Committee as follows:

KPI 1: ROI Hurdle
15% per annum calculated using the following formula:

Change in EBITDA year on year/amount invested in operating assets during the year.

KPI 2: Revenue Hurdle
Tranche 1/FY21 – Revenue growth of 60%
Tranche 2/FY22 – Revenue growth of 40%
Tranche 3/FY23 – Revenue growth of 25%

Subsequent to 30 June 2021, 1,600,000 of these options lapsed as a result of the resignation of Mr Fabio Baglioni on 30 July 2021. In addition, KPIs with respect to an additional 1,733,333 options with an expiry date of 14 April 2024 were not satsified and have subsequently lapsed. Accordingly, as at the date of this report, the Company had on issue 3,466,667 options to KMPs under the post-IPO option plan.

In addition, subsequent to 30 June 2021, the Board has exercised its discretion to allocate the following new options to management as part of the Company's remuneration scheme to reward the diligent execution of the corporate strategy and to ensure retention of the key talent needed to deliver strategic outcome in the interest of shareholders:

John Kelly	333,333 options
William Souter	213,333 options
Mark Smith	213,333 options
Total	**759,999 options**

These options are exercisable at $0.25 per option and expire on 14 April 2024. In addition, these options are conditional upon the executive remaining employed by the Company and in the case of John Kelly, on Shareholder approval of the allocation.

(c) Other Options

During the current financial year, the Company issued 4,000,000 new options to Bondi Partners as part of Bondi Partners' appointment to assist with the development and execution of its US go-to-market strategy and commecial engagements across both private and public sectors as announced to the ASX on 30 April 2021.

Tranche 1 (2,000,000 options) will vest on 31 Octover 2022 subject to Atomo extending Bondi Partners' consultancy engagement for a further period of at least six (6) months (in Atomo's sole discretion). These options are exercisable at an exercise price of $0.40 per option and expire or 30 April 2024.

Tranche 2 (2,000,000 options) are exercisable at $0.60, vest on 30 April 2022 and expire on 30 April 2024.

The Company has adopted the 'Black-Scholes' option model to determine the fair value of these options. The valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
31/05/2021	30/04/2024	$0.22	$0.40	60.00%	0.00%	0.25%	$0.051
31/05/2021	30/04/2024	$0.22	$0.60	60.00%	0.00%	0.25%	$0.031

In estimating the expected volatility, management relied on historical volatility trends applicable to the Company's shares. Accordingly, the expected volatility used to assess the fair value of options may not necessarily be indicative of the actual volatility of Atomo's shares over the exercise period(s).

09 DIRECTORS' DECLARATION

DIRECTOR'S DECLARATION

In the Directors' opinion:

- the attached financial statements and notes comply with the *Corporations Act 2001*, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2021 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The Directors have been given the declarations required by section 295A of the *Corporations Act 2001*.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the *Corporations Act 2001*.

On behalf of the Directors:

John Keith
Chair

27 August 2021
Sydney

10 INDEPENDENT AUDITOR'S REPORT

INDEPENDENT AUDITOR'S REPORT

To the members of Atomo Diagnostics Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Atomo Diagnostics Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2021, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies and the Directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

(i) Giving a true and fair view of the Group's financial position as at 30 June 2021 and of its financial performance for the year ended on that date; and

(ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the Directors of the Company, would be in the same terms if given to the Directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition

Key audit matter	How the matter was addressed in our audit
As disclosed in Note 3, the Group recognised revenue from the sale of goods and revenue from freight of $6,715,659 for the year ended 30 June 2021. Revenue was identified as a key audit matter as it is a key performance indicator to the users of the financial report.	Our procedures, amongst others, include: - Reviewed whether the revenue recognition policies are in accordance with Australian Accounting Standards and the Group's accounting policies described in Note 1; - Substantive testing around year end to ensure revenue is correctly recorded in the period to which it relates; - Selected a sample of revenue transactions during the year and substantively test to ensure revenue has been appropriately reflected in the financial statements for the year ended 30 June 2021; and - Reviewed material revenue contracts and assessed if the Group's accounting treatment is in accordance with the Australian Accounting Standards.

Share based payments

Key audit matter	How the matter was addressed in our audit
As disclosed in the remuneration report and note 28 of the financial statements, in prior periods, the Company issued incentive options to key management personnel, which the Company has accounted for as share-based payments. During the period the Company also issued share options to other stakeholders. Share-based payments and the subsequent measurement is a complex accounting area including assumptions utilised in the fair value calculations and judgements regarding the incentive options issued during the year and the subsequent measurement of those issued in prior periods. There is a risk in the financial statements that amounts are incorrectly recognised and/or inappropriately disclosed. Refer to note 1 and 2 of the financial report for a description of the accounting policy and significant estimates and judgements applied to these transactions.	Our procedures, amongst others, include: - Ensured that any share based payments issued during the financial period have been valued appropriately as at grant date; - Performed a review of the key estimates and assumptions applied in the accounting for share based payments, making an assessment as to whether they remain appropriate for the current period; - Performed a review of the share based payments to ensure these are being accounted for appropriately across the vesting period; - Ensured that options have been accounted for appropriately in accordance with AASB 2 Share Based Payments; and - Ensured disclosure in the financial statements and remuneration report are adequate to meet the requirements of the applicable accounting standards and the *Corporations Act 2001*.

Other information

The Directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2021, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf

This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in the Directors' report for the year ended 30 June 2021.

In our opinion, the Remuneration Report of Atomo Diagnostics Limited, for the year ended 30 June 2021, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO Audit Pty Ltd

Gareth Few
Director

Sydney
27 August 2021


atomo
Self Test

11 SHAREHOLDER INFORMATION

The shareholder information set out below was applicable as at 27 August 2021.

NUMBER OF SECURITY HOLDERS

At the specified date, there were 8,454 holders of ordinary shares (quoted and unquoted) and 12 holders of options (unquoted) over ordinary shares. These were the only classes of equity securities on issue.

DISTRIBUTION OF EQUITABLE SECURITIES

Analysis of number of equitable security holders by size of holding:

	Number of holders	Number of shares
1 to 1,000	328	224,299
1,001 to 5,000	3,489	9,521,511
5,001 to 10,000	1,533	12,515,053
10,001 to 100,000	2,718	89,273,166
100,001 and over	386	457,063,778
Total	**8,454**	**568,597**

EQUITY SECURITY HOLDERS

Twenty largest holders of quoted ordinary shares

The names of the twenty largest holders of quoted ordinary shares are listed below:

	Ordinary shares	
	Number held	% of total share issued
Dalraida Holdings Pty Limited	66,160,000	11.64
Global Health Investment Fund I LLC	64,811,280	11.40
HSBC Custody Nominees (Australia) Limited	46,427,252	8.17
Walker Group Holdings Pty Ltd	37,660,718	6.62
National Nominees Limited	22,976,845	4.04
J P Morgan Nominees Australia Pty Limited	14,258,766	2.51
Grand Challenges Canada	11,390,824	2.00
Liverbird Pty Ltd	10,931,653	1.92
I D E Pty Ltd	9,032,248	1.59
Mark Andrew Smith	7,790,224	1.3
John Michael Kelly	7,370,248	1.30
Leo James Lynch & Judith Anne Beswick	7,321,121	1.29
Mr Ian Fredrick Johnson	6,079,560	1.07
Ruth Karen Devney	5,626,408	0.99
Citicorp Nominees Pty Limited	5,373,057	0.94
Bosana Nominees Pty Ltd	5,081,496	0.89
Sokolov Pty Ltd	4,500,000	0.79
Poul Damgaard Hansen	4,340,184	0.76
Miss Lisa Marie Mackenzie	3,351,968	0.59
Alex Griffiths	3,283,872	0.58
Total top 20 shareholders	**343,767,724**	**60.46**

SUBSTANTIAL HOLDERS*

Substantial holders in the company as disclosed in substantial holding notices given to the Company are set out below:

	Ordinary shares	
	Number held	% of total shares issued
John Kelly	73,530,248	13.11
Global Health Investment Fund LLC	63,851,280	11.38
Walker Group Holdings Pty Ltd	37,660,718	6.70
Ellerston Capital Limited	34,375,000	6.13
Total substantial shareholders	**209,417,246**	**37.32**

*Based on substantial holder notices lodged

UNQUOTED RESTRICTED SECURITIES

There were 159,907,471 unquoted ordinary shares and 13,733,333 unquoted options over ordinary shares subject to a restriction period as follows:

Restriction period	Class of security	Number	Number of holders	Date escrow period ends
24 months ASX restriction from date of official quotation	ORD	159,907,471	12	16 April 2022
24 months ASX restriction from date of official quotation	Options	13,733,333	7	16 April 2022

OPTION HOLDING DISTRIBUTION

Size of option holding	Number of holders	Number of options	% of Issued Options
1 to 1,000	-	-	-
1,001 to 5,000	-	-	-
5,001 to 10,000	-	-	-
10,001 to 100,000	-	-	-
100,001 and over	12	22,959,851	100
Total	**12**	**22,959,851**	**100**

UNQUOTED OPTIONS OVER ORDINARY SHARES

There were 22,959,851 unquoted options over ordinary shares on issue, 13,733,333 of which were restricted securities as follows:

Unquoted options – description	Number of options	Number of holders
Options exercisable at $0.15625 expiring 6 Apr 2022 (subject to ASX escrow restriction ending 16 April 2022)	6,000,000	5
Options exercisable at 0.15625 expiring 11 Apr 2023 (subject to ASX escrow restriction ending 16 April 2022)	4,800,000	5
Options exercisable at $0.25 expiring various dates (subject to ASX escrow restriction until 16 April 2022)	2,933,333	2
Options exercisable at $0.15625 expiring 6 Apr 2022	800,000	1
Options exercisable at $0.03 expiring 16 Apr 2022	2,293,184	1
Options exercisable at $0.25 expiring on various dates	2,133,334	2
Options exercisable at $0.40 expiring 30.4.2024	2,000,000	1
Options exercisable at $0.60 expiring 30.4.2024	2,000,000	1

No person holds 20% or more of the unquoted options on issue.

VOTING RIGHTS

The voting rights attached to ordinary shares are set out below:

Ordinary shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.

UNMARKETABLE PARCELS

There are 1,707 holders of an unmarketable parcel of shares based on the closing market price of $0.240 at the specified date.

OTHER ASX REQUIRED INFORMATION

During the period between admission to the Official List of ASX and the end of the reporting period, the Company used the cash and assets in a form readily convertible to cash that it had at the time of admission to the ASX, in a way consistent with its business objectives. This statement is made pursuant to ASX Listing Rule 4.10.19.

12 CORPORATE DIRECTORY

Directors	**John Keith** (Chair & Non-Executive Director) **John Kelly** (Managing Director & CEO) **Curt LaBelle** (Non-Executive Director) **Paul Kasian** (Non-Executive Director) **Connie Carnabuci** (Non-Executive Director)
Company Secretary	**Gillian Nairn**
Registered office	Level 2 701 - 703 Parramatta Road Leichhardt NSW 2040 +61 2 9099 4750
Principal place of business	Level 2 701 - 703 Parramatta Road Leichhardt NSW 2040 +61 2 9099 4750
Share registry	**Link Market Services Limited** Level 12 680 George Street Sydney NSW 2000 1300 554 474
Auditor	**BDO Audit Pty Ltd** Level 11, 1 Margaret Street Sydney NSW 2000
Solicitors	**HWL Ebsworth Lawyers** Level 14, Australia Square 264 - 278 George Street Sydney NSW 2000
Stock exchange listing	Atomo Diagnostics Limited shares are listed on the Australian Securities Exchange (ASX code: AT1)
Corporate Governance	Atomo Corporate Governance Statement: https://atomodiagnostics.com/governance/
Website	**www.atomodiagnostics.com**



ATOMO DIAGNOSTICS LIMITED
ACN 142 925 684